Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act: Guidance for FDA Staff and Stakeholders

Draft Guidance
This guidance is being distributed for comment purposes only.

Although you can comment on any guidance document at any time (see 21 CFR 10.115(g)(5)), to ensure that FDA considers your comment on this draft guidance document before we begin work on the final version of the guidance document, submit either electronic or written comments on the draft guidance document within 120 days of publication in the Federal Register of the notice announcing the availability of the draft guidance document. Submit electronic comments to https://www.regulations.gov. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number FDA-2021-N-0553 listed in the notice of availability that publishes in the Federal Register.

For questions regarding this draft guidance document, contact the Center for Food Safety and Applied Nutrition (CFSAN) at CFSANCompliancePolicy@FDA.HHS.GOV.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Food Safety and Applied Nutrition

April 2022
I. Introduction ....................................................................................................................... 4

II. Definitions and Abbreviations Used in This Guidance ................................................. 5
A. Definitions of Terms Used in This Guidance ............................................................... 5
B. Table of Abbreviations Used in This Guidance ............................................................. 9

III. Background ..................................................................................................................... 10
A. What is Food Allergy? .................................................................................................... 10
B. Preventing IgE-mediated Food Allergic Reactions ...................................................... 12
C. FDA’s Regulations, Guidance, Assistance, and Communications Applicable to Food Allergens .......................................................................................................................... 13
   1. Regulatory framework applicable to food allergens in the United States .................... 13
   2. FDA’s Food Code ............................................................................................................. 17
   3. FDA’s communications to the public ............................................................................ 17
D. Specific Requests for FDA to Evaluate Certain Foods as Food Allergens of Public Health Importance .................................................................................................................. 17

IV. Scientific Factors Relevant to the Public Health Importance of a Non-Listed Food Allergen ........................................................................................................................................ 18
A. Evidence of IgE-mediated Food Allergy ....................................................................... 19
B. Prevalence of IgE-mediated Food Allergy .................................................................... 21
C. Severity of IgE-mediated Food Allergic Reactions ....................................................... 24
D. Allergenic Potency ......................................................................................................... 27

V. Identifying and Systematically Evaluating the Body of Evidence Applicable to Our Scientific Factors .......................................................................................................................... 29
A. Preliminary Identification of Published Scientific Literature ......................................... 30
B. Preliminary Identification of Community Reports in Surveillance Databases and Other Sources .......................................................................................................................... 30
C. Systematic Evaluation of Published Scientific Literature and Community Reports 31

1. Narrowing the identified body of published scientific literature ........................................ 31
2. Systematic evaluation of the strength of the identified evidence ...................................... 32
3. Systematic evaluation of community reports ................................................................. 35
4. Systematic evaluation of the severity of an IgE-mediated food allergic reaction .......... 36

VI. FDA’s Evaluation of the Public Health Importance of a Non-Listed Food Allergen 37

A. FDA’s Evaluation of the Identified Body of Evidence Applicable to Our Scientific Factors .............................................................................................................................................. 37

1. Factor #1: Evidence of IgE-mediated food allergy .......................................................... 38
2. Factor #2: Prevalence of an IgE-mediated food allergy in the U.S. population ............... 39
3. Factor #3: Severity of IgE-mediated food allergic reactions ........................................... 40
4. Factor #4: Allergenic potency .......................................................................................... 41

B. FDA’s Evaluation of Information Relevant to the Labeling and Production of Food Containing a Food Allergen ................................................................................................................................. 42

C. How FDA Intends to Consider the Total Body of Evidence ........................................ 43

VII. Stakeholder Submission of a Citizen Petition .......................................................... 43

VIII. References .................................................................................................................. 44

IX. Appendix A – Additional Considerations .................................................................. 48

A. “Community Reports” Regarding Food Allergens ..................................................... 48

B. Codex Criteria for Evaluating the Public Health Importance of Food Allergens .... 49

C. Development of Other Examples of Criteria for Evaluating the Public Health Importance of Food Allergens .............................................................................................................................. 51

D. Report of the National Academies of Sciences, Engineering, and Medicine on Food Allergy .................................................................................................................................................. 51
This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or we) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

I. Introduction

This guidance is intended for:

- FDA staff who are responsible for evaluating, on FDA’s initiative or in response to a citizen petition submitted in accordance with 21 CFR 10.30, the public health importance of a non-listed food allergen, which for the purpose of this guidance means a food allergen other than one of the major food allergens (i.e., milk, eggs, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybeans, and sesame) listed in the Federal Food, Drug, and Cosmetic Act (FD&C Act); and
- Stakeholders who intend to submit a citizen petition asking FDA to establish regulatory requirements based on the public health importance of a non-listed food allergen (“applicable stakeholders”) or who are interested in how FDA generally intends to evaluate the public health importance of such food allergens.

This guidance addresses substances that are currently consumed in food or have previously been consumed in food, within or outside the United States, such that there is a body of information

---

1 This guidance has been prepared by the Compliance Policy Staff in the Office of Compliance, the Food Labeling and Standards Staff in the Office of Nutrition and Food Labeling, and the Office of Regulations and Policy, all in the Center for Food Safety and Applied Nutrition at the U.S. Food and Drug Administration.

2 In April 2021, the Food Allergy Safety, Treatment, Education, and Research Act of 2021 (FASTER Act) amended section 201(qq) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) to add sesame to the definition of “major food allergen.” This amendment applies to “any food that is introduced or delivered for introduction into interstate commerce on or after January 1, 2023” (Public Law 117-11).
about adverse reactions experienced by consumers who ingest the substance. This guidance does not address the potential that a substance that would be new to the food supply might be a food allergen. This guidance also does not address scientific research regarding potential cross-reactivity to a known food allergen and how this research could help determine whether a substance in food could be a food allergen.

This guidance describes the approach we generally intend to take when we evaluate the public health importance of a non-listed food allergen by specifying:

- The scientific factors that we generally intend to consider when evaluating the public health importance of a non-listed food allergen;
- Other information, relevant to the labeling and production of food containing the food allergen, that we generally intend to consider when evaluating the public health importance of a non-listed food allergen; and
- Our recommendations for how to identify and evaluate the body of evidence applicable to an evaluation of the public health importance of a non-listed food allergen.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word ‘should’ in FDA guidance documents means that something is suggested or recommended, but not required.

II. Definitions and Abbreviations Used in This Guidance

A. Definitions of Terms Used in This Guidance

Table 1 defines several terms for the purpose of this guidance.

<table>
<thead>
<tr>
<th>Term</th>
<th>What It Means</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaphylaxis</td>
<td>An acute, potentially life-threatening syndrome with multi-systemic manifestations due to the rapid release of inflammatory mediators</td>
</tr>
<tr>
<td>Allergen cross-contact</td>
<td>The unintentional incorporation of a food allergen into a food</td>
</tr>
</tbody>
</table>

3 The term “food” is defined in section 201(f) of the FD&C Act (21 U.S.C. 321(f)) and means (1) articles used for food or drink for man or other animals, (2) chewing gum, and (3) articles used for components of any such article. Food also includes dietary supplements, as defined in section 201(ff) of the FD&C Act (21 U.S.C. 321(ff)). This guidance pertains to human food.

4 For information on the topic of clinically cross-reactive food allergy, see section IV.A.
<table>
<thead>
<tr>
<th>Term</th>
<th>What It Means</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergenic potency</td>
<td>The amount of food allergenic protein required to elicit an IgE-mediated food allergic reaction in an already sensitized individual</td>
</tr>
<tr>
<td>Applicable stakeholder</td>
<td>A stakeholder who intends to submit a citizen petition asking us to evaluate the public health importance of a non-listed food allergen</td>
</tr>
<tr>
<td>Clinically cross-reactive food allergy</td>
<td>Cross-reactivity in which the Immunoglobulin E antibody (IgE) directed to one food binds to another food and causes IgE-mediated responses (including clinical symptoms) to that other food. (See also the definition of cross-reactivity.)</td>
</tr>
<tr>
<td>Community report</td>
<td>A report, regarding a known or suspected food allergen in a food product, that is submitted to a surveillance database, a research query, or other request for information, or that is otherwise collected and described (e.g., as a patient case study or a diagnostic food challenge study reported in the scientific literature). A community report can be submitted or prepared by consumers, health care professionals, industry, researchers, government agencies, non-government agencies, or other stakeholders. Some community reports (such as adverse event reports and case studies) describe an allergic reaction experienced by an individual to a food product, whereas other community reports (usually called product complaints) call FDA’s attention to a potential problem (such as labeling that does not disclose that a food product is or contains a food allergen). See Appendix A for further discussion on community reports.</td>
</tr>
<tr>
<td>Cross-reactivity</td>
<td>Reactivity of the immune system observed when a protein in one food shares characteristics with a protein from another substance food. (See also the definition of clinically cross-reactive food allergy.)</td>
</tr>
<tr>
<td>Documented sensitized individual</td>
<td>An individual with documented evidence of IgE sensitization to relevant food or component(s) of food (e.g., confirmed by positive skin percutaneous test (SPT) or in vitro allergen specific IgE test)</td>
</tr>
<tr>
<td>Term</td>
<td>What It Means</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Food</td>
<td>The term “food” is defined in section 201(f) of the FD&amp;C Act and means (1) articles used for food or drink for man or other animals, (2) chewing gum, and (3) articles used for components of any such article (21 U.S.C. 321(f)). Food includes dietary supplements, as defined in section 201(ff) of the FD&amp;C Act (21 U.S.C. 321(ff)). This guidance pertains to human food.</td>
</tr>
<tr>
<td>Food allergen</td>
<td>The food or component(s) of a food (often a protein) that elicits specific, IgE-mediated immunologic reactions (Ref. 1 and Ref. 2)</td>
</tr>
<tr>
<td>Food allergic reaction</td>
<td>A reaction, characterized by a set of clinical symptoms, experienced by a sensitized individual exposed to a food allergen</td>
</tr>
<tr>
<td>Food allergy</td>
<td>An adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food (Ref. 1 and Ref. 2)</td>
</tr>
<tr>
<td>Food challenge</td>
<td>A clinical procedure or intervention in which gradually increasing food doses are administered to elicit reactivity to the food. Food challenges can be unblinded (open), single-blinded (in which only the researcher doing the study knows what the participant is receiving), or double-blinded blinded (in which neither the researcher nor the participant know what the participant is receiving).</td>
</tr>
<tr>
<td>Food hypersensitivity</td>
<td>An adverse food reaction, occurring in a population of sensitive individuals, that can be either mediated by immune mechanisms (i.e., food allergy) or mediated by mechanisms that are not immune mechanisms (i.e., food intolerance)</td>
</tr>
<tr>
<td>Food intolerance</td>
<td>Food adverse reaction that is not immune-mediated (e.g., lactose intolerance)</td>
</tr>
<tr>
<td>Frequency dose–response</td>
<td>The population distribution of doses eliciting or provoking an IgE-mediated food allergic reaction</td>
</tr>
<tr>
<td>Historical information</td>
<td>Generally available information (e.g., in published scientific literature and in community reports)</td>
</tr>
<tr>
<td>Major food allergen</td>
<td>Milk, eggs, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybeans, and sesame (effective January 1, 2023) and, with few exceptions, a food ingredient that contains protein derived from one of these foods (see section 201(qq) of the FD&amp;C Act)</td>
</tr>
<tr>
<td>Objective signs of food allergy</td>
<td>Symptoms that are elicited by food challenge and visible or ascertainable to an observer (e.g., hives, swelling, wheezing)</td>
</tr>
</tbody>
</table>
## Terms and Definitions

<table>
<thead>
<tr>
<th>Term</th>
<th>What It Means</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral allergy syndrome</td>
<td>Food allergic condition limited to tingling, itching, or swelling of the lips or mouth after oral contact with food allergen</td>
</tr>
<tr>
<td>Probable food allergy rate</td>
<td>Prevalence estimate of food allergy derived from questionnaires in a population of self-reported allergic individuals</td>
</tr>
<tr>
<td>Reactivity (or elicitation)</td>
<td>Development of allergic signs or symptoms when the food or component(s) of food is consumed</td>
</tr>
<tr>
<td>Self-reported allergic individual</td>
<td>An individual with self-reported history of food allergic reactions (i.e., typical and reproducible symptoms in close temporal association (e.g., within a few hours) of food consumption) and self-reported doctor-confirmed diagnosis with evidence of IgE sensitization to relevant food or component(s) of food (e.g., positive reaction in SPT or <em>in vitro</em> allergen specific IgE test)</td>
</tr>
<tr>
<td>Self-reported reactive individual</td>
<td>An individual who self-reports having had a food allergic reaction without also self-reporting evidence of IgE sensitization to relevant food or component(s) of food</td>
</tr>
<tr>
<td>Self-reported sensitized individual</td>
<td>An individual who self-reports evidence of IgE sensitization to relevant food or component(s) of food (e.g., a self-report of positive SPT or <em>in vitro</em> allergen specific IgE test) without also self-reporting food allergic reaction</td>
</tr>
<tr>
<td>Sensitization</td>
<td>Production of IgE specific to the food or component(s) of food</td>
</tr>
<tr>
<td>Severity dose-response</td>
<td>The gradient of severity of IgE-mediated food allergic reactions caused by the food</td>
</tr>
<tr>
<td>Subjective symptoms of food allergy</td>
<td>Symptoms that are elicited by food challenge but not visible or ascertainable to an observer (e.g., tingling, chest tightness, nausea)</td>
</tr>
<tr>
<td>Threshold (as described in scientific literature)</td>
<td>• Level below which it is unlikely that a food allergic individual would experience an adverse effect (Ref. 3)</td>
</tr>
<tr>
<td></td>
<td>• In food challenge studies, the challenge dose interval between the highest challenge dose not to elicit an objective sign or symptom and the lowest challenge dose to elicit an objective sign or symptom (Ref. 4 and Ref. 5)</td>
</tr>
</tbody>
</table>
Contains Nonbinding Recommendations
Draft-Not for Implementation

<table>
<thead>
<tr>
<th>Term</th>
<th>What It Means</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well-characterized allergic individual</td>
<td>An individual with documented history of IgE-mediated food allergic reactions [i.e., typical and reproducible clinical allergic signs or symptoms in close temporal association (e.g., within a few hours) of food consumption or positive food challenge] and documented evidence of IgE sensitization to relevant food or component(s) of food (e.g., positive reaction in SPT or in vitro allergen specific IgE test)</td>
</tr>
</tbody>
</table>

B. Table of Abbreviations Used in This Guidance

See Table 2 for abbreviations used in this guidance.

Table 2. Abbreviations used in this guidance

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>What It Means</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999 Codex criteria</td>
<td>Criteria, recommended to Codex by the Food Allergens Labelling Panel, for determining whether there are foods, in addition to the list of foods adopted by Codex in 1999, whose presence should always be declared in the list of ingredients on a food label because of their allergenic properties</td>
</tr>
<tr>
<td>Allergen labeling requirements of the FD&amp;C Act</td>
<td>The major food allergen labeling requirements in section 403(w) of the FD&amp;C Act</td>
</tr>
<tr>
<td>CAERS</td>
<td>CFSAN Adverse Event Reporting System</td>
</tr>
<tr>
<td>CGMP</td>
<td>Current good manufacturing practice</td>
</tr>
<tr>
<td>CFSAN</td>
<td>Center for Food Safety and Applied Nutrition</td>
</tr>
<tr>
<td>Codex</td>
<td>Codex Alimentarius Commission</td>
</tr>
<tr>
<td>DBPCFC</td>
<td>Double-blinded, placebo-controlled food challenge</td>
</tr>
<tr>
<td>ED</td>
<td>Eliciting dose</td>
</tr>
<tr>
<td>ED01, ED05, ED10, ED50</td>
<td>Eliciting dose required to produce an IgE-mediated food allergic reaction in 1%, 5%, 10%, or 50% of the allergic population, respectively</td>
</tr>
<tr>
<td>ER</td>
<td>Emergency room</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FD&amp;C Act</td>
<td>Federal Food, Drug, and Cosmetic Act</td>
</tr>
<tr>
<td>FALCPA</td>
<td>Food Allergen Labeling and Consumer Protection Act of 2004</td>
</tr>
<tr>
<td>FASTER Act</td>
<td>Food Allergy Safety, Treatment, Education, and Research Act of 2021</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of Recommendations Assessment, Development, and Evaluation</td>
</tr>
<tr>
<td>IgE</td>
<td>Immunoglobulin E antibody</td>
</tr>
<tr>
<td>IgE-mediated food allergy</td>
<td>Food allergy that is mediated by IgE</td>
</tr>
<tr>
<td>ILSI-EU</td>
<td>International Life Sciences Institute-Europe</td>
</tr>
<tr>
<td>NASEM</td>
<td>National Academies of Sciences, Engineering, and Medicine</td>
</tr>
</tbody>
</table>
### Abbreviation

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>What It Means</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-listed food allergen</td>
<td>A food allergen other than one of the major food allergens (i.e., milk, eggs, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybeans, and sesame (sesame effective January 1, 2023)) listed in the FD&amp;C Act</td>
</tr>
<tr>
<td>OAS</td>
<td>Oral allergy syndrome</td>
</tr>
<tr>
<td>OFC</td>
<td>Oral food challenge– open or single-blinded (but not double-blinded)</td>
</tr>
<tr>
<td>Part 117</td>
<td>Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food in 21 CFR part 117</td>
</tr>
<tr>
<td>Preventive controls requirements</td>
<td>The requirements (primarily in subparts C and G of 21 CFR part 117, with associated requirements in subparts A, D, E, and F of part 117) for domestic and foreign facilities that are required to register under section 415 of the FD&amp;C Act to establish and implement hazard analysis and risk-based preventive controls for human food</td>
</tr>
<tr>
<td>SPT</td>
<td>Skin percutaneous test (“skin prick test”)</td>
</tr>
</tbody>
</table>

### III. Background

#### A. What is Food Allergy?

Food allergy is a form of food hypersensitivity. Adverse reactions to food due to food hypersensitivity can be broadly grouped into reactions that are mediated by either immune mechanisms (food allergic reactions) or non-immune mechanisms (primarily food intolerances) (Ref. 1). For example:

- Adverse reactions that are immune-mediated can be caused by:
  - IgE-mediated mechanisms (e.g., IgE-mediated anaphylactic reaction to peanuts);
  - Non-IgE-mediated mechanisms (e.g., adverse reaction to gluten in the case of celiac disease);
  - Mixed immune mechanisms (e.g., eosinophilic gastroenteropathies⁵); or
  - Cell-mediated mechanisms (e.g., contact dermatitis).
- Adverse reactions that are not immune-mediated can be caused by:
  - Metabolic mechanisms (e.g., lactose intolerance);
  - Pharmacologic mechanisms (e.g., reaction to caffeine);
  - Toxicological mechanisms (e.g., scombroid toxin poisoning); or

⁵ Although IgE-mediated responses to foods associated with this group of disorders have been identified, the main pathogenesis of this group of disorders is believed to be non IgE-mediated.
Food allergy can be broadly defined as an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food (Ref. 1 and Ref. 2). A food allergen is the food or component(s) (often a protein) of a food that elicits specific immunologic reactions (Ref. 1).

While many different types of food allergies have been identified, food allergies that are recognized to be the most severe and immediately life-threatening are those that are mediated by immunoglobulin E antibodies (IgE) because IgE-mediated food allergic reactions are capable of triggering anaphylaxis, which can be fatal (Ref. 1 and Ref. 3). Immune-mediated mechanisms that are not IgE-mediated (such as mechanisms associated with celiac disease and contact dermatitis), and mechanisms that are not immune-mediated (such as lactose intolerance) typically are not associated with anaphylaxis or other immediately life-threatening conditions.

IgE-mediated food allergic reactions can occur within a few minutes to hours after a sensitized individual consumes the applicable food allergen. IgE-mediated food allergic reactions can have a wide range of clinical manifestations that, if untreated, can lead to serious adverse health consequences, including death (Ref. 1 and Ref. 2). IgE-mediated food allergic reactions can involve a single organ system such as the skin (e.g., pruritis, erythema, urticaria, angioedema, eczema), eyes (e.g., conjunctivitis, periorbital swelling), nose (e.g., rhinitis, sneezing), oral cavity (e.g., swelling and itching of lips, tongue, or palate), or gastrointestinal tract (e.g., reflux, colic, abdominal pain, nausea, vomiting, diarrhea). The most severe IgE-mediated food allergic reactions (generally referred to as anaphylaxis) involve the “shock organs” of the respiratory tract or cardiovascular system and involve signs or symptoms such as cough, wheezing, difficulty breathing, swelling of the larynx or vocal cords, fainting, and low blood pressure. These anaphylactic reactions can lead to loss of consciousness, asphyxiation, shock, or death.

The focus of this guidance is IgE-mediated food allergy, which is a type of food hypersensitivity that has been studied extensively and is associated with the most severe and immediately life-threatening allergic reactions, including anaphylaxis. Likewise, the discussions in this guidance of “food allergens” is limited to those foods that elicit IgE-mediated immune reactions.

---

6 The Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA) identifies eight major food allergens (or food groups): milk, eggs, fish (e.g., bass, flounder, cod), crustacean shellfish (e.g., shrimp, crab, lobster), tree nuts (e.g., almonds, walnuts, pecans), peanuts, wheat, and soybeans. At the time that FALCPA was enacted, these eight foods were believed to account for 90 percent of food allergies and most serious reactions to foods (section 202(2)(A) of FALCPA (21 U.S.C. 343 note); Ref. 6 and Ref. 7). More than 160 foods are known to cause IgE-mediated food allergic reactions of varying severity, many with relatively low prevalence rates, with some as low as single cases (Ref. 7).

7 See Table 1 for the definitions of “objective signs of food allergy” and “subjective symptoms of food allergy.” In the remainder of this guidance, we generally refer to “signs or symptoms” without noting that “signs” are objective and “symptoms” are subjective.

8 A food allergen may also be associated with reactions that are not IgE-mediated or not immune mediated.
B. Preventing IgE-mediated Food Allergic Reactions

Although treatments for IgE-mediated food allergies currently are being developed, the most effective strategy for preventing IgE-mediated food allergic reactions is for allergic consumers to avoid foods that are or contain food allergens.\(^9\) Constant food vigilance and fear of accidental life-threatening reactions with every meal are daily, patient-centered challenges that can accompany management of IgE-mediated food allergy. These patient-centered challenges have been shown to negatively impact the quality of life of food allergic individuals and their caregivers (Ref. 2).

As discussed in section IV.A, some consumers have clinically cross-reactive IgE-mediated food allergies (Ref. 11) in which a consumer who experiences an IgE-mediated allergic reaction to one food allergen (e.g., cashews, which are a tree nut) also experiences IgE-mediated allergic reactions to another food allergen (e.g., pistachios, which also are a tree nut (Ref. 1)). While most individuals with cross-reactive allergies to foods, such as tree nuts, understand the reaction risks for cross-reactivity and are cautioned to avoid all tree nuts to prevent allergic reactions, other cross-reactive food allergies may not be known or obvious to the food allergic consumer. In the latter case, because individuals known to be allergic to a food allergen may have inherent potential for IgE-mediated reactions to other cross-reactive food allergens, first-time and/or any inadvertent consumption of a cross-reactive food allergen by this allergic individual(s) can also lead to allergic reactions. A particularly challenging situation is one in which a food allergen has not been on the U.S. market for an extended period of time or is not commonly used as an ingredient in food, because potential cross-reactivity to the food allergen would not be well-recognized in the allergic population.\(^{10}\)

As discussed in section III.C.1, in general the FD&C Act and our implementing regulations broadly apply to the production of food that is or contains a food allergen through statutory and regulatory provisions regarding: (1) food labeling; (2) food production; and (3) the safety of substances added to food. The label of packaged foods provides allergic consumers and their caregivers information that they can use to avoid foods that contain food allergens. The most relevant information is the food allergen source from which a food or food ingredient is derived. For example, the source of the food “tofu” is the major food allergen “soy,” and the source of the ingredient “lactoferrin” is the major food allergen “milk.” The potential for allergen cross-contact can be reduced or eliminated through CGMPs and preventive controls. The CGMP requirements and preventive controls requirements apply only to the already identified major food allergens.

Complete avoidance of food allergens remains difficult. This is exemplified by the high percentage (40-50\%) of food allergic individuals who report reactions to major food allergens and other foods in the community every year (Ref. 1, Ref. 13, and Ref. 14). A subset of these

\(^9\) FDA recently approved the use of oral immunotherapy to treat children and adolescents with peanut allergies (Ref. 8). The oral immunotherapy is indicated for the mitigation of allergic reactions, including anaphylaxis, that can occur with accidental exposure to peanut (Ref. 9 and Ref. 10). Oral immunotherapy currently is available only for peanuts, is used in combination with a peanut avoidance diet, and is not a cure.

\(^{10}\) For example, see “Consumer Advice on Lupin” (Ref. 12), advising that people who are allergic to peanuts could also react to lupin, a legume belonging to the same plant family as peanuts.
IgE-mediated food allergic reactions results in anaphylaxis presenting to emergency rooms (Ref. 2). Causes for these reactions are multifactorial – e.g., they can be due to consumption of non-packaged food products in which labeling of the already identified food allergens is not required, allergen cross-contact during food production, or unclear or absent allergen information on packaged food products when a food allergen is not an already identified major food allergen subject to the allergen labeling requirements of the FD&C Act (Ref. 13). For example, a food allergen that is not a major food allergen and is added as a spice, flavoring, or color may be declared using a collective term as allowed for in 21 CFR 101.22. As another example, the food allergen source of a food or ingredient that is not an already identified major food allergen is not required to be disclosed as part of the common or usual name of the food or ingredient.11

C. FDA’s Regulations, Guidance, Assistance, and Communications Applicable to Food Allergens

1. Regulatory framework applicable to food allergens in the United States

In general, the provisions of the FD&C Act and our implementing regulations that are most relevant to food that is or contains a food allergen address: (1) food labeling; (2) food production (e.g., manufacturing, processing, packing, and holding food); and (3) the safety of substances added to food.

With respect to food labeling, the general misbranding provisions in section 403 of the FD&C Act (21 U.S.C. 343) provide us with broad authority to provide consumers with information, on the food label, about substances in the food, including substances that are food allergens. We have established several regulations that implement these misbranding provisions of the FD&C Act and also specify some special circumstances that may be relevant to some food allergens. For example, a food label must bear the common or usual name of the food, if it has one, and the common or usual name of each ingredient if the food is made from two or more ingredients (section 403(i) of the FD&C Act (21 U.S.C. 343(i))). A common or usual name must accurately identify or describe, in as simple and direct terms as possible, the basic nature of the food or its characterizing properties or ingredients and can either be the name established by common use or the name required by a regulation (21 CFR 102.5). For example, the label of a food made with sugar must declare this ingredient by its common or usual name (“sugar”) rather than the chemical name “sucrose” (see 21 CFR 101.4(b)(20); section 403(i) of the FD&C Act)). However, specific labeling provisions apply to the declaration of some food ingredients. For example, spices, natural flavor, and artificial flavor may be declared using a collective term (e.g., “spice,” “natural flavor,” or “artificial flavor,” respectively) without identifying the particular spice or flavor, except for substances obtained by cutting, grinding, drying, pulping, or similar processing of tissues derived from fruit, vegetable, meat, fish, or poultry (e.g., powdered or granulated onions, garlic powder, and celery powder), which are commonly understood by consumers to be food rather than flavor and must be declared by their common or usual name (see 21 CFR 101.22(h)(1) and (3)).12 Likewise, some colorings may be declared using the

11 For example, our food labeling regulations do not currently require that the common or usual name “tahini” disclose the food allergen source – “sesame.”
12 For the purpose of this guidance:
collective term “color” (see 21 CFR 101.22(k)(2)). As another example, incidental additives that are present in a food at insignificant levels and do not have any technical or functional effect in that food are exempt from the ingredient declaration requirements (see 21 CFR 101.100(a)(3)).

In 2004, the Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA) amended the FD&C Act to provide us with additional, specific authority regarding the labeling of a food (other than a raw agricultural commodity) that bears or contains a “major food allergen.”

Under section 403(w) of the FD&C Act (21 U.S.C. 343(w)), a food is misbranded if it contains a major food allergen and fails to declare that major food allergen on its label in the manner specified using the major food allergen’s common or usual name, including the name of the food source from which the major food allergen is derived. Section 201(qq)(1) of the FD&C Act (21 U.S.C. 321(qq)(1)) defines a “major food allergen,” in part, as any of the following:

- Milk,
- Egg,
- Fish (e.g., bass, flounder, or cod),
- Crustacean shellfish (e.g., crab, lobster, or shrimp),
- Tree nuts (e.g., almonds, pecans, or walnuts),
- Wheat,
- Peanuts, and
- Soybeans.

When FALCPA was enacted, these eight foods and food groups, out of more than 160 identified food allergens, accounted for 90% of IgE-mediated food allergic reactions in the U.S. When drafting FALCPA, Congress made clear that the new statutory requirements did not alter our existing authority under the FD&C Act to require a label or labeling for other food allergens (21 U.S.C. 343 note). Also, section 403(x) of the FD&C Act gives us explicit authority to require by

---

13 An example of an incidental additive is a processing aid that is added to a food during the processing of such food but is removed in some manner from the food before the food is packaged in its finished form (see 21 CFR 101.100(a)(3)(ii)(a)).

14 We issued guidance to help the public understand our implementation of the amendments, including what foods and manufacturers are subject to the amendments and labeling requirements (Ref. 15). We also issued guidance to clarify the information we need when considering whether to exempt certain ingredients derived from major food allergens from the allergen labeling requirements (Ref. 16).
regulation the disclosure of spices, flavorings, colorings, or incidental additives that are, or contain, food allergens other than the eight major food allergens.15

In April 2021, the Food Allergy Safety, Treatment, Education, and Research Act of 2021 (FASTER Act) amended section 201(qq) of the FD&C Act to add sesame to the definition of “major food allergen.” This amendment applies to “any food that is introduced or delivered for introduction into interstate commerce on or after January 1, 2023” (Public Law 117-11).

With respect to food production, our regulation entitled “Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food” (21 CFR part 117; “part 117”) establishes requirements applicable to establishments that manufacture, process, pack, or hold human food. Part 117 includes current good manufacturing practice (CGMP) requirements to prevent allergen cross-contact. Allergen cross-contact is the unintentional incorporation of a food allergen into a food; part 117 defines “food allergen” to mean a major food allergen as defined in section 201(qq) of the FD&C Act. (See the definitions of “allergen cross-contact” and “food allergen” in 21 CFR 117.3.) Allergen cross-contact occurs between foods that have different food allergen profiles (the food allergen sources present or absent in a food). The processing characteristics of a food can affect the potential for allergen cross-contact to occur. For example, when using shared equipment, it is more difficult to prevent allergen cross-contact when producing foods with high viscosity (such as nut butters) and using only dry cleaning methods than when producing foods with low viscosity (such as many beverages) and using wet cleaning methods due to challenges associated with cleaning all traces of a high-viscosity food from shared food-contact surfaces using dry cleaning methods. As another example, when using adjacent processing lines, it is more difficult to prevent allergen cross-contact when producing foods (such as peanuts and milk powder) that are prone to the creation of dust than when producing foods (such as many beverages) that are not prone to the creation of dust.

Part 117 also establishes specific requirements (commonly called “preventive controls requirements”) for domestic and foreign facilities that are required to register under section 415 of the FD&C Act to establish and implement hazard analysis and risk-based preventive controls for human food as mandated by the FDA Food Safety Modernization Act of 2011 (FSMA). With few exceptions,16 these preventive controls requirements specify that food manufacturers must implement a food safety plan that includes a hazard analysis to identify known or reasonably foreseeable hazards that require a preventive control. Preventive controls must significantly minimize or prevent hazards. When a hazard requiring a preventive control is a

---

15 We relied on this authority, in part, to require the labeling of carmine and cochineal extract in foods (see § 73.100 and 74 FR 207, January 5, 2009).
16 See 21 CFR 117.5 for the exemptions from the preventive controls requirements. For example, the preventive controls requirements do not apply to a facility that is a “qualified facility” (e.g., because it is a very small business) as that term is defined in part 117. (Alternative requirements apply to these facilities.) The preventive controls requirements also do not apply with respect to activities that are subject to “hazard analysis and critical control point” requirements in 21 CFR part 120 (for juice) or 21 CFR part 123 (for seafood) if a facility is required to comply with, and is in compliance with, 21 CFR part 120 or 21 CFR part 123, respectively, with respect to such activities. In addition, nonprofit food establishments, restaurants, and retail food establishments are not required to register as a food facility (see 21 CFR 1.226) and generally are inspected by State or local regulatory agencies, often under State or local laws and regulations based on FDA’s Food Code, which is a model code available for adoption by local, state, and other jurisdictions to apply to food establishments at the retail level that provide food directly to consumers (Ref. 17).
major food allergen, preventive controls also must ensure that the food manufactured, processed, packed, or held by the facility will not be adulterated under section 402 of the FD&C Act or misbranded under section 403(w) of the FD&C Act. (See 21 CFR 117.126, 117.130(a)(1) and (b)(1)(ii), and 117.135(a)(1), (c)(2), and (c)(3).)

With respect to the safety of substances added to food, under sections 201(s) and 409 of the FD&C Act (21 U.S.C. 321(s) and 21 U.S.C. 348), any substance that is intentionally added to food is a food additive that is subject to premarket review and approval by FDA, unless the substance is generally recognized, among qualified experts, as having been adequately shown to be safe under the conditions of its intended use (commonly referred to as a “generally recognized as safe” or “GRAS” substance), or unless the use of the substance is otherwise excepted from the definition of a food additive (e.g., if the substance meets the definition of “color additive” in section 201(t) of the FD&C Act). The procedures for premarket review and approval of a food additive petition are established in 21 CFR part 171. A notification procedure whereby any person may notify FDA of a conclusion that a substance is GRAS under the conditions of its intended use is established in 21 CFR part 170, subpart E.

Under sections 201(t) and 721 of the FD&C Act (21 U.S.C. 321(t) and 21 U.S.C. 379), a substance that meets the definition of “color additive” must be listed in an Agency regulation prescribing the conditions under which such additive may be safely used. In contrast to the definition of food additive, the definition of color additive has no provision for GRAS substances and, thus, all substances that are color additives are subject to premarket review and listing by FDA. The procedures for premarket review of a color additive petition are established in 21 CFR part 71.

When available, information regarding IgE-mediated food allergic reactions that are known to occur reproducibly on exposure to a given food substance are relevant to an evaluation of the safety of a substance under the conditions of its intended use. In most circumstances when a substance is subject to premarket review and approval by FDA, the substance is not already in the U.S. food supply and, thus, reactivity information from prior food exposure by the U.S. population would not be available during FDA’s premarket review. However, we can and have used our authorities regarding the safety of substances added to food to amend the conditions of use specified in a regulation if information regarding allergic reactions to a food substance becomes available after that food substance has entered the U.S. food supply. For example, in 2009 we relied, in part, on the authority in sections 201(t) and 721 of the FD&C Act to revise our requirements for cochineal extract and carmine17 by requiring their declaration by name on the label of all food products18 that contain these color additives (see § 73.100 and 74 FR 207, January 5, 2009).

---

17 Cochineal extract is a color additive that is permitted for use in foods and drugs in the United States. The related color additive carmine is permitted for use in foods, drugs, and cosmetics. The Color Additive Amendments of 1960 (Public Law 86–618, 74 Stat. 397) amended the FD&C Act to add the definition of “color additive,” establish conditions under which color additives may be safely used and require FDA to publish a provisional list of color additives that were already in use or were certified as color additives prior to July 12, 1960. FDA included both cochineal extract and carmine in this provisional list. Following FDA’s review of color additive petitions submitted in 1964 (for carmine) and 1968 (for cochineal extract), FDA permanently listed both carmine and cochineal extract in the color additive regulations.

18 The revised requirements also apply to the label of all cosmetic products that contain cochineal extract or carmine.
2. FDA’s Food Code

Food allergen information has been included in FDA’s Food Code\(^{19}\) (Ref. 17) since 2005 and includes a definition of “major food allergen” and a provision under “Demonstration of Knowledge” [Subparagraph 2-102.11(C)(9)] specifying that the person in charge of a food establishment shall have an understanding of the foods identified as major food allergens and the symptoms that a major food allergen could cause in a sensitive individual. The Food Code also allows integration of the allergen labeling requirements of the FD&C Act (see Table 2 for definition) to reflect the additional requirements that apply to food that is packaged at the retail level [Subparagraph 3-602.11(B)(5)]. However, the allergen labeling requirements of the FD&C Act do not apply to foods provided by a retail food establishment that are placed in a wrapper or container in response to a consumer's order - such as the paper or box used to convey a sandwich that has been prepared in response to a consumer's order.

3. FDA’s communications to the public

We make safety information available to stakeholders on our Web site (https://www.fda.gov). For example, we have issued “Consumer Advice on Lupin” (Ref. 12), advising that people who are allergic to peanuts could also react to lupin, a legume belonging to the same plant family as peanuts.

D. Specific Requests for FDA to Evaluate Certain Foods as Food Allergens of Public Health Importance

Since FALCPA was enacted, we have received several requests to evaluate a food as a food allergen of public health importance. For example:

- In 2008, we received a citizen petition asking us to “[amend] ... FALCPA to include barley and rye in the list of common allergens requiring disclosure on packaging” (Ref. 18);
- In 2014, we received a citizen petition asking us to require that sesame seeds and sesame products be regulated in a manner similar to a major allergen under FALCPA and listed specifically by name (“sesame”) in ingredient lists of foods, and to add sesame to the list of allergens in a 2005 “Compliance Policy Guide Sec. 555.250 Statement of Policy for Labeling and Preventing Cross-contact of Common Food Allergens” (Ref. 19) to address both labeling and cross-contact issues related to sesame in food manufacturing practices (Ref. 20); and
- In 2015, we received a citizen petition asking us to “issue a regulation to include garlic as an ingredient or allergen on food labels” and specifically “require food labels to list garlic as an allergen” (Ref. 21).

\(^{19}\) FDA publishes the Food Code, a model that assists food control jurisdictions at all levels of government by providing them with a scientifically sound technical and legal basis for regulating the retail and food service segment of the industry (restaurants and grocery stores and institutions such as nursing homes). Local, state, tribal, and federal regulators use the FDA Food Code as a model to develop or update their own food safety rules and to be consistent with national food regulatory policy.
The data and information submitted in support of these requests varied. We denied the request regarding barley and rye because the petition did not include adequate information to show that rye and barley are common causes of severe IgE-mediated food allergies (Ref. 22). We denied the request regarding garlic because: (1) the petition did not provide evidence to show that garlic is a common cause of severe food allergies; and (2) garlic is not considered a spice for purposes of ingredient labeling and must be declared as “garlic” rather than being declared collectively under the term “spice” (21 CFR 101.22(a)(2)). Thus, consumers who are allergic to garlic can avoid consuming it by examining the ingredient statements on the foods they purchase and avoiding those foods where garlic is listed (Ref. 23).

We responded to the request regarding sesame by publishing a notice inviting additional data and other information on the prevalence and severity of sesame allergies in the United States and the prevalence of sesame-containing foods that are sold in the United States but are not required to declare sesame by name as an ingredient (83 FR 54594 (October 30, 2018)). We stated our interest in learning more about the prevalence and severity of sesame allergies in the United States and the prevalence of sesame-containing foods sold in the United States that are not required to declare sesame as an ingredient. We also stated that we were requesting this data and other information to inform possible regulatory action on sesame to protect and promote the public health. Key scientific data requested for sesame fell into the following two categories:

- Prevalence of allergies and allergic reactions due to sesame in the United States, including the proportion of allergic reactions attributed to undisclosed sesame in food products; and
- Prevalence and amounts of undisclosed sesame in foods.

After considering the data and information submitted to that notice, we announced the availability for public comment of a draft guidance document titled, “Voluntary Disclosure of Sesame as an Allergen: Guidance for Industry (Draft Guidance)” (Ref. 24) (85 FR 71920 (November 12, 2020)). This guidance initiative was intended to provide food manufacturers with FDA’s current views on sesame as an allergen and provide recommendations regarding the voluntary disclosure of sesame in certain circumstances where such disclosure is not currently required, as well as help individuals who are allergic to sesame identify those foods that contain sesame as an ingredient.20

**IV. Scientific Factors Relevant to the Public Health Importance of a Non-Listed Food Allergen**

We have identified the following scientific factors that we generally intend to consider when evaluating the public health importance of a food allergen in the United States:

- Factor #1: evidence of IgE-mediated food allergy
- Factor #2: the prevalence of an IgE-mediated food allergy in the U.S. population

---

20 The FASTER Act amended section 201(qq) of the FD&C Act to add sesame to the definition of “major food allergen,” effective January 1, 2023.
Contains Nonbinding Recommendations  
Draft-Not for Implementation  

- Factor #3: the severity of IgE-mediated food allergic reactions  
- Factor #4: the allergenic potency  

Our scientific factors are consistent with the 1999 Codex criteria (Ref. 25), the revised criteria recommended by the International Life Sciences Institute-Europe (ILSI-EU) (Ref. 26), published frameworks from ILSI-EU and public, private, and academic partners in Europe for the evaluation of public health importance of a food allergen (Ref. 26 and Ref. 27), publications from ILSI-EU and public, private, and academic partners in Europe that evaluate published frameworks (Ref. 28 and Ref. 29), and the National Academy of Sciences, Engineering and Medicine (NASEM) (Ref. 2; the NASEM report). See Appendix A for further discussion of these criteria and frameworks.  

A. Evidence of IgE-mediated Food Allergy  

An IgE-mediated food allergic reaction is characterized by a two-step immune process – i.e., sensitization and reactivity. Sensitization is the production of IgE specific to the food or food component, often a protein. Reactivity (or elicitation) is the development of clinical allergic signs or symptoms when the food or component of food is consumed. The sensitization and reactivity steps can occur independently in certain individuals, so that evidence of sensitization alone, or reactivity alone, does not establish clear evidence that an adverse reaction to a food is an IgE-mediated food allergic reaction. Therefore, the best approach to a doctor diagnosis of IgE-mediated food allergy is robust evidence of a cause-effect relationship between oral exposure to the food or component of food and elicitation of signs or symptoms (which demonstrates reactivity) in individuals who are known to be sensitized to the food (which demonstrates sensitization).  

Evidence of IgE-mediated food allergy can be obtained from several sources and methodologies, provided that the sources and methodologies provide evidence of both sensitization and reactivity. The “gold standard” method for obtaining evidence of IgE-mediated food allergy is the double-blinded, placebo-controlled food challenge (DBPCFC) in a population of documented sensitized individuals, because reactivity to food exposure is directly and impartially assessed in documented sensitized individuals. By documented sensitized individuals, we mean individuals with documented evidence of IgE sensitization to the relevant food or component(s) of food (e.g., evidence confirmed by skin percutaneous test (SPT; often called skin prick test) or in vitro allergen specific IgE test), but without documented evidence of IgE-mediated food allergic reaction. Conducting the DBPCFC in documented sensitized individuals satisfies the first criterion (sensitization), and elicitation of clinical allergic signs or symptoms during the food challenge provides evidence for the second criterion (reactivity). However, outside of specialized clinical centers, DBPCFC are rarely performed.  

When a DBPCFC is not available, other historical information (i.e., from the scientific literature or community reports) can still provide robust evidence of IgE-mediated food allergy, provided that the information provides evidence of both sensitization and reactivity. For example, under appropriate conditions, a positive open or single-blinded oral food challenge (OFC) in a documented sensitized individual can provide robust evidence of IgE-mediated food allergy. Also, evidence of IgE-mediated food allergy can be obtained from historical information.
describing observations or reports of typical, reproducible, and temporally related signs or symptoms of IgE-mediated food allergic reactions in sensitized individuals, including documented sensitized individuals and self-reported sensitized individuals. Evidence of clinical reactivity in documented sensitized individuals, in whom IgE sensitization has been confirmed, is more robust evidence of IgE-mediated food allergy than evidence in self-reported sensitized individuals, in whom IgE sensitization is not confirmed. Similarly, evidence of positive OFC or other observations of typical, reproducible, and temporally related signs or symptoms associated with food consumption consistent with IgE-mediated allergy is more robust evidence of IgE-mediated food reactivity than reports of unspecified allergic reaction to food alone. Evaluating reactivity information from sensitized individuals in these datasets is important, because it reduces the potential for signs or symptoms reported as food “allergic” reactions to be due to confounders such as an intolerance that might be associated with the food.21

Research has identified and characterized specific proteins that have allergenic properties and occur in many different foods. These food allergenic proteins have been recognized by reputable national and international organizations. For example, the World Health Organization and International Union of Immunological Societies (WHO/IUIS) Allergen Nomenclature Subcommittee is an international organization responsible for maintaining and developing a unique, unambiguous and systematic nomenclature for allergenic proteins and maintains an allergen database that contains approved and officially recognized allergens (Ref. 30). Identification of a protein from a food in the database maintained by the WHO/IUS Allergen Nomenclature Subcommittee is supporting evidence that the food or component(s) of food is a food allergen – i.e., that adverse reactions to the food or component(s) of food are IgE-mediated.22

Clinical evidence of foods or food components (such as proteins) causing IgE-mediated reactions from exposure by non-oral routes (e.g., skin, inhalation) can be used as supporting evidence that an adverse reaction to a food or component of food is IgE-mediated, but generally would not be sufficient, by itself, to be considered definitive evidence that an adverse reaction to a food or component of food is IgE-mediated. The most definitive evidence of IgE-mediated food allergy is from reactions observed or associated with oral or sublingual (i.e., under the tongue) exposure.

Observations in historical information regarding food elimination diets that lead to resolution of chronic signs or symptoms such as eczema or persistent gastrointestinal complaints in individuals with self-reported sensitization to the food generally do not provide robust evidence of IgE-mediated food allergy unless accompanied by documentation of sensitization and information that typical signs or symptoms are also elicited by food consumption or food challenge in those individuals in a time frame consistent with an IgE-mediated reaction.

21 For example, the symptoms of lactose intolerance can be a confounder in the diagnosis of milk allergy in individual patients.

22 See the WHO/IUS submission form for the criteria for submission of a new allergen to the WHO/IUIS allergen nomenclature database (Ref. 31). Section 2.5 of the submission form states: “Allergens are incorporated into the Official List of Allergens only if protein-specific binding of IgE from at least 5 sera of patients allergic to the respective allergen source, and NOT to those without allergy to the source (preference: test with sera from 3 allergic to other sources and 2 without allergies). IgE binding should be tested (demonstrated) to the purified (natural or recombinant) allergen, as well as to an extract of the source material that represents the source of allergy (e.g. fruit, pollen, insect, animal parts).” Section 2.5.1 of the submission form requires evidence of both reactivity and IgE sensitization.
In clinically cross-reactive food allergy, IgE directed to a food allergen in one food can bind to, and cause IgE-mediated reactions to, an allergen in another food, likely due to the presence of similar proteins in both foods (Ref. 11). As such, historical information, or observed data, regarding clinically cross-reactive food allergies (Ref. 11) to a food in individuals sensitized to other cross-reactive foods may provide further evidence of IgE-mediated allergy to that food. For example, a consumer who is known to be allergic to one food allergen (e.g., cashews) could eat a pistachio and experience an immediate allergic reaction. Because both cashews and pistachios are tree nuts and have been recognized to be cross-reactive allergens (Ref. 1), evidence of clinically cross-reactive food allergy to pistachio in a cashew allergic consumer is likely to provide evidence that the individual has IgE-mediated food allergy to pistachio as well. However, while cross-reactive food allergies are important concerns to consider for food allergens, the most definitive evidence that the food causes IgE-mediated food allergy for the purposes of this guidance is evidence that the food directly causes IgE-mediated reactions in individuals who are sensitized to the food.23

B. Prevalence of IgE-mediated Food Allergy

Information to estimate the prevalence of IgE-mediated food allergy has come from a number of different sources and methodologies, including prospective data from clinic patients who have undergone systematic diagnostic evaluation with clinical testing to the food, self-reported data of food allergy reactions in community reports, and retrospective review of patient medical records with diagnosis codes related to food allergy. Because there are many different types of food hypersensitivities that are not IgE-mediated and other disease processes that may mimic allergic reactions, the most robust estimate of the prevalence rate of an IgE-mediated food allergy is obtained from a defined population of individuals with: (1) documented history of IgE-mediated food allergic reactions (i.e., typical and reproducible signs or symptoms in close temporal association (e.g., within a few hours) of food consumption or positive food challenge); and (2) documented evidence of IgE sensitization to the relevant food or food proteins (e.g., positive reaction in SPT or in vitro allergen specific IgE test) (Ref. 1 and Ref. 2). For the purpose of this guidance, we refer to such individuals as “well-characterized allergic individuals.” However, obtaining this type of prevalence rate estimate at the national level is difficult. The 2016 NASEM report (Ref. 2) found that “evidence on the true prevalence of food allergy in the [United States] is obscured by insufficient or inconsistent data and variable methodology.” This report did not find prevalence rate estimations for any IgE-mediated food allergy relevant to the U.S. population based on DBPCFC or other robust clinical parameters. Instead, epidemiological studies that estimate “probable food allergy rates” in the general population in the United States are based on self-reported responses to questionnaires distributed to a defined number of participants (commonly called reporters).

23 This guidance only addresses food allergy caused by substances that are currently consumed in food or have previously been consumed in food and does not address scientific research regarding potential cross-reactivity to a known food allergen and how this research could help determine whether a substance in food could be a food allergen.
In some epidemiological studies to estimate probable food allergy rates, the questionnaires only ask for self-reported information about the foods associated with allergic reactions, whereas in other epidemiological studies to estimate probable food allergy rates, the questionnaires also ask for self-reported information about signs or symptoms, treatment, doctor visits, diagnostic tools, and doctor diagnosis in addition to self-reported information about the foods associated with allergic reactions. Neither type of epidemiological study can clearly establish that the reporters are well-characterized allergic individuals, because the data collected during these studies are self-reported rather than clinically documented. However, the design of the questionnaires used in these studies can increase the probability that the self-reports correctly report food allergy. For example, food allergy rates estimated from epidemiological studies in the general population based only on self-reports of foods associated with an allergic reaction tend to overestimate population prevalence estimates of IgE-mediated allergy to the food (Ref. 1), because many reporters confuse food allergy for other forms of adverse food reactions. This overestimation may be reduced when the questionnaires also ask for self-reported information about signs or symptoms of the allergic reaction(s), treatment or doctor visit, diagnostic tools, and doctor diagnosis in addition to self-reported information about the foods associated with allergic reactions, because a trained health professional who evaluates the data from the questionnaires could review the additional data to determine whether it is consistent with typical, reproducible, and temporally related signs or symptoms of an allergic reaction and whether there may be evidence of IgE sensitization.

The most robust estimates of probable food allergy rates are obtained from epidemiological studies that: (1) use validated questionnaires and consistent methods to assess the type and characteristics of signs or symptoms experienced during allergic reactions; (2) collect self-reported data from a randomly selected, nationally representative population; (3) ask the reporters to self-report all foods that cause a food allergic reaction (rather than prompt the reporters about only specific foods that cause a food allergic reaction); and (4) ask reporters to describe signs or symptoms, treatment or doctor visits, diagnostic tools, and doctor diagnosis related to food allergy. Asking reporters to identify all foods that cause a food allergy or food allergic reaction can help to provide comparative information on the relative frequency of food allergies to specific food allergens, identify food allergens that have higher or lower prevalence in the population studied, and provide comparative information on the relative number and frequency of IgE-mediated food allergic reactions reported for each food. Asking reporters to also describe the associated adverse effects (signs or symptoms of the allergic reaction(s), treatment or doctor visits, diagnostic tools, and doctor diagnosis) can help strengthen the individual self-reports as likely, or probable, IgE-mediated food allergic reactions.

Another type of epidemiological study that has been used (Ref. 32) to estimate the prevalence rate for a food allergen is an epidemiological study in which researchers look for evidence of IgE sensitization in blood samples collected from the general population. Although this type of study can identify sensitized individuals, it provides no evidence that exposure to the food elicits an allergic reaction in the sensitized individuals and could overestimate the prevalence rate of a food allergen, because some of the sensitized individuals might not be allergic individuals. Several types of prevalence data generally are not sufficiently robust, by themselves, to estimate prevalence of IgE-mediated food allergy. For example, the following types of prevalence data generally are not robust for the reasons given:
Prevalence estimates based on IgE sensitization rates or other clinical parameters from local or regional U.S. populations (e.g., academic clinical center patient populations, and individuals presenting to local or regional hospital systems) – such data are not nationally representative of the U.S. population.

Prevalence data from other countries or geographical areas – the U.S. population might have different genetic background, consumption frequencies, or practices for the food(s).

Information about the frequency of IgE-mediated food allergy and/or IgE-mediated food allergic reactions in community reports from non-questionnaire methods, such as surveillance databases – such reports usually describe a number of allergic individuals without providing sufficient information to understand the baseline number of allergic or non-allergic individuals in the population of reporters.

Information about the frequency of IgE-mediated food allergy and/or IgE-mediated food allergic reactions from surveys based on retrospective review of patient medical records with diagnosis codes related to food allergy – such diagnosis codes are not always specific for IgE-mediated food allergy.

Prevalence information is more likely to be available for foods that have been on the U.S. market for an extended period of time or are commonly used as an ingredient in food. In addition, the probable food allergy rate of individual foods generally is not static. Food consumption patterns can change over time – e.g., when newly developed food products that use a food allergen as an ingredient lead to an increased consumption of that food allergen by the U.S population. As a result, information queried over successive time periods could identify changes in probable food allergy rates for individual foods. When multiple reports regarding prevalence data are available, the most recent prevalence reports (e.g., data obtained in the prior 10 years) would more closely reflect the prevalence of allergy to the food in the current population.

In 2004, FALCPA discussed the prevalence of the eight foods that it identified as the major food allergens collectively, stating that these eight foods represented about 90% of all food allergies in the U.S. population and that approximately 2% of adults and about 5% of infants and young children in the United States suffer from food allergies. In 2010, published U.S. food allergy guidelines estimated probable food allergy rates based on self-reported food allergy symptoms to each of these eight major food allergens in the U.S. population to be in the range of 0.3 percent to 3 percent (Ref. 1). Based on more recent 2015-2016 U.S. national surveys (Ref. 33 and Ref. 34), individual probable food allergy rates based on self-reported symptoms highly suggestive of IgE-mediated allergy alone (“convincing” food allergy) for each of these eight major food allergens were estimated to be in the range of 0.6 to 2.9% and 0.5 to 2.2% for adults and children, respectively. Individual probable food allergy rates based on more robust parameters of self-reported “convincing” symptoms and doctor diagnosis (“confirmed” food allergy) for these eight major food allergens in children were estimated to be in the range of 0.2 to 1.8% (Ref. 33). The 2015-2016 U.S. national surveys also reported individual probable food allergy rates for sesame (Ref. 33 and Ref. 34).

See Table 3 for estimated prevalence of IgE-mediated food allergy in the U.S. population for the already identified major food allergens based on probable food allergy rates.
Table 3. Estimated prevalence of probable food allergy to individual already-identified major food allergens in the U.S. population

<table>
<thead>
<tr>
<th>Population</th>
<th>Milk</th>
<th>Soy</th>
<th>Peanut</th>
<th>Tree Nuts</th>
<th>Fish</th>
<th>Shellfish</th>
<th>Egg</th>
<th>Wheat</th>
<th>Sesame (effective 1/1/23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All ages, self-reported symptoms (% total) (Ref. 1)*</td>
<td>3.0</td>
<td>0.6</td>
<td>0.6</td>
<td>0-4.1</td>
<td>0.6</td>
<td>1.2</td>
<td>1.0</td>
<td>0.2-1.3</td>
<td>N/A</td>
</tr>
<tr>
<td>Children, (“convincing”) symptoms alone (age 0-17; % total) (Ref. 33)</td>
<td>1.9</td>
<td>0.5</td>
<td>2.2</td>
<td>1.2</td>
<td>0.6</td>
<td>1.3</td>
<td>0.9</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Children, (“confirmed”) signs or symptoms and doctor diagnosis (age 0-17; % total) (Ref. 33)</td>
<td>1.0</td>
<td>0.2</td>
<td>1.8</td>
<td>0.9</td>
<td>0.3</td>
<td>0.8</td>
<td>0.7</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Adults, (“convincing”) symptoms alone (age 18+; % total) (Ref. 34)</td>
<td>1.9</td>
<td>0.6</td>
<td>1.8</td>
<td>1.2</td>
<td>0.9</td>
<td>2.9</td>
<td>0.8</td>
<td>0.8</td>
<td>0.2</td>
</tr>
</tbody>
</table>

* The authors reviewed the available data and reported the prevalence of probable food allergy as either a single number or a range based on the findings of their review.

C. Severity of IgE-mediated Food Allergic Reactions

As discussed in section III.A, IgE-mediated food allergic reactions can have a wide range of clinical manifestations that can involve a single or multiple organ systems. These clinical manifestations can range from relatively mild local reactions to severe anaphylactic reactions. Without prompt medical intervention with epinephrine or other treatment measures, severe clinical manifestations can progress to various adverse health outcomes, including asphyxiation, respiratory distress, or cardiovascular collapse, often resulting in hospitalization. Severe allergic reactions can be fatal; an analysis of temporal patterns and demographic associations for anaphylaxis in the United States from 1999 to 2010 identified 164 fatalities associated with anaphylactic reactions to food allergens (Ref. 33).
There currently are no validated biomarkers for assessing or predicting reaction severity, and it is likely that several factors (e.g., individual sensitivity, the amount and characteristics of the food consumed, underlying co-morbid conditions such as asthma, and the effects of other foods and drugs) all interact to determine the course and severity of each IgE-mediated food allergic reaction (Ref. 1). However, data obtained from clinical studies and from community reports can be used to evaluate the severity of IgE-mediated food allergic reactions at both the individual and population levels. Evidence of the severity of an IgE-mediated food allergic reaction collected from clinical studies, in which a trained health care professional reports or describes, and documents, signs or symptoms generally is more robust than evidence collected from community reports, in which signs or symptoms are self-reported by individuals and may not be objectively scrutinized.

One approach to evaluating severity data obtained from clinical studies or from community reports is the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) system, which provides a comprehensive and transparent methodology to develop recommendations for the diagnosis, treatment, and management of patients (Ref. 35). A scientific publication describes a GRADE system for scoring the severity of an IgE-mediated food allergic reaction to an eliciting dose of food (Ref. 36). This GRADE system was developed by integrating eight published schemes or grading systems for the severity of IgE-mediated food allergic reactions, each of which was independently developed and widely recognized (Ref. 36). Another approach to evaluating severity data obtained from information such as DBPCFC studies and from community reports is “PRACTALL” (Ref. 37), which has a numerical grading system for several distinct types of allergic reactions (skin, upper respiratory, lower respiratory, gastrointestinal, and cardiovascular/neurologic).

Factors that are important in characterizing the severity of reaction(s) to the food include the type of elicited signs or symptom(s), the extent of organ involvement, use of certain medications (such as epinephrine autoinjector) to manage reactions, evidence of reaction leading to medical visit or hospitalization, or other adverse health consequence. In general, signs or symptoms graded as moderate or severe in this GRADE system pose more risk to the health of allergic individuals than signs or symptoms graded as mild.

See Table 7 in section V.C.4 for an example of a GRADE system for severity data. The GRADE system in Table 7 is adapted from the GRADE systems published in Ref. 36 and Ref. 37.

The most robust evidence of the severity of an IgE-mediated food allergic reaction is collected from a study that reports objective signs in well-characterized allergic individuals evaluated in a clinical setting (e.g., clinic, hospital), that are classified according to a scientifically accepted classification system and treated using an accepted algorithm. In general, the clinical setting of such studies provides a context to assess severity of reaction due to “real-life” allergen exposures in a population of well-characterized allergic individuals presenting to clinical care facilities. This information may also help provide information on the total magnitude of severe reactions in the population to understand the public health burden of allergic reactions to the food.

Documentation of objective signs observed during food challenge studies that are conducted in well-characterized allergic individuals, evaluated as part of a research protocol or clinical
Evaluation, are also useful. However, these studies may provide less robust evidence of the severity of an IgE-mediated food allergic reaction in allergic individuals than “real-life” allergen exposures because such food challenge studies generally are conducted in a step wise manner to enhance subject safety. As such, most challenges are conducted with a slow escalation of food allergen exposure and terminated at the first sign of an objective reaction prior to elicitation of severe allergic reactions in most participants (Ref. 1 and Ref. 2). Thus, food challenge studies may not capture the total magnitude of potential severe reactions from exposure to the food allergen.

Evidence of the severity of an IgE-mediated food allergic reaction can be collected from community reports. The quality of the evidence depends on the type of signs or symptoms and the individuals reporting the signs or symptoms. For example, as shown in Table 6 in section V.C.2, the quality of the evidence is greater when:

- The community reports are from well-characterized allergic individuals;
- The reported reactions are objective (i.e., signs such as hives, swelling, and wheezing that are visible to an observer) rather than subjective (i.e., symptoms such as tingling and chest tightness that are not visible to an observer); and
- The reported signs or symptoms are typical of allergic reactions.

In 2004, FALCPA discussed the severity of eight major food allergens collectively, stating that roughly 30,000 individuals require emergency room treatment each year and 150 individuals die each year because of allergic reactions to food. To assess more current markers of severity for major food allergens, we reviewed published scientific literature that identified some objective measures on number or frequency of severe IgE-mediated food allergic reactions reported in U.S. children or adults with probable food allergy to individual already identified major food allergens, including sesame (Ref. 33 and Ref. 34). See Table 4 for the severity information that we extracted from this published scientific literature.

Table 4. Objective measures of severity of IgE-mediated food allergic reactions in US children (ages 0-17) or adults (age 18+) with probable food allergy to individual already identified major food allergens

<table>
<thead>
<tr>
<th>Children or adults with probable food allergy</th>
<th>Milk</th>
<th>Soy</th>
<th>Peanut</th>
<th>Tree Nuts</th>
<th>Fish</th>
<th>Shellfish</th>
<th>Egg</th>
<th>Wheat</th>
<th>Sesame (effective 1/1/23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of children reported to have severe food allergy (Ref. 33)</td>
<td>25.3</td>
<td>36.8</td>
<td>59.2</td>
<td>56.1</td>
<td>49.0</td>
<td>48.7</td>
<td>28.1</td>
<td>36.7</td>
<td>27.2</td>
</tr>
<tr>
<td>% of children reported to have ER* visits-lifetime (Ref. 33)</td>
<td>47.1</td>
<td>53.5</td>
<td>50.4</td>
<td>49.4</td>
<td>69.8</td>
<td>54.9</td>
<td>56.4</td>
<td>43.7</td>
<td>58.2</td>
</tr>
</tbody>
</table>
Children or adults with probable food allergy

<table>
<thead>
<tr>
<th>Allergen</th>
<th>Milk</th>
<th>Soy</th>
<th>Peanut</th>
<th>Tree Nuts</th>
<th>Fish</th>
<th>Shellfish</th>
<th>Egg</th>
<th>Wheat</th>
<th>Sesame (effective 1/1/23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of adults reporting severe reactions (Ref. 34)</td>
<td>39.3</td>
<td>45.4</td>
<td>67.8</td>
<td>61.3</td>
<td>56.5</td>
<td>56.8</td>
<td>39.4</td>
<td>42.6</td>
<td>39.7</td>
</tr>
<tr>
<td>% of adults reporting ER visits- lifetime (Ref. 34)</td>
<td>47.0</td>
<td>48.3</td>
<td>62.3</td>
<td>54.3</td>
<td>60.1</td>
<td>45.3</td>
<td>55.0</td>
<td>43.6</td>
<td>66.2</td>
</tr>
</tbody>
</table>

*ER = emergency room

**D. Allergenic Potency**

All food allergens that cause IgE-mediated food allergy have the potential to cause anaphylaxis or other severe health consequences if the food allergen is consumed (Ref. 1 and Ref. 2). Allergenic potency is the amount of food allergenic protein required to elicit an IgE-mediated food allergic reaction in a sensitized individual (Ref. 26).

Allergenic potency can vary between individuals and foods. An example of a measure of allergenic potency of a food allergen is the lowest amount (or threshold) of a food allergen required to cause an IgE-mediated food allergic reaction. This can be measured at an individual or population level. Evidence regarding the potency of a food allergen can be collected from studies conducted in a large number of allergic individuals; it also can be collected from case or community reports. As with evidence regarding the severity of an IgE-mediated food allergic reaction, evidence regarding the potency of a food allergen generally is more robust when it is collected from studies, in which a trained health care professional reports or describes, and documents, information (rather than from community reports, in which information is self-reported).

One useful endpoint for assessing the allergenic potency of an individual food is the “frequency dose-response” – i.e., the population distribution of doses eliciting or provoking an IgE-mediated food allergic reaction (Ref. 26). The most robust measure to determine frequency dose-response is data collected from graded food challenge studies conducted over a wide range of doses in a large number of well-characterized allergic individuals. In such studies, the amount of food allergen (in grams of protein) is measured prior to consumption and given in escalating doses

---

24 This threshold measure of allergenic potency can help provide information about the potential for any incidental exposure to food to cause an allergic reaction in an individual or in a population of individuals (Ref. 26 and Ref. 27).

25 The ED information obtained from these studies is similar to the lowest observed adverse effect level (LOAEL) obtained from toxicological studies (Ref. 3).
until a food allergic reaction is observed. The challenge dose associated with the observed reaction is called the eliciting dose (ED) and this dose represents the relative potency of the food allergen for that given individual. Distributions of individual ED information can be modeled to generate probabilities of reactions at a given ED within the population of challenge subjects. For example, international efforts, by organizations such as the Allergen Bureau of Australia & New Zealand, have applied quantitative risk modeling approaches to studies of threshold EDs to food(s) from different food challenge study datasets to determine population ED distributions for different food(s) (Ref. 38 and Ref. 39). From these ED distributions, probabilistic information on what EDs could cause a reaction in a given percentage of food allergic individuals within the population can be estimated. For example, dose potencies can be estimated from EDs predicted to produce an IgE-mediated food allergic reaction in 1 percent, 5 percent, or 10 percent of the allergic population (referred to as the ED01, ED05, or ED10, respectively). Also, a measure of mean dose potency could then be the ED predicted to produce an IgE-mediated food allergic reaction in 50 percent of a specific allergic population (referred to as the ED50). This mean potency provides a robust statistical estimate to compare potencies between different food allergens (Ref. 27).

Another endpoint for assessing allergenic potency is the “severity dose–response” – i.e., the gradient of severity of IgE-mediated food allergic reactions caused by the food. The probability of a severe IgE-mediated food allergic reaction from a relatively small amount of a food allergen is greater when the severity dose-response ratio is high (i.e., the food allergen has a high probability of severe IgE-mediated food allergic reactions from low dose exposures) (Ref. 26).

Currently, at the individual level, the most robust measure of allergenic potency is ED information obtained from a graded food challenge study. However, individual allergenic dose potency information can also be obtained through evaluation of case or community reports when the allergen dose exposure can be estimated from quantitative information about both the amount of food product likely consumed during a reaction and the concentration of food allergen in that food product. Quantitative information about both the amount of food product consumed (e.g., in grams or ounces of food product) and the concentration of food allergen in that food product (e.g., parts per million (ppm)) can distinguish between circumstances in which an IgE-mediated food allergic reaction associated with a relatively small amount of food product is due

---

26 The DBPCFC is considered to be the best format for an oral challenge, but single blinded or open challenges could also be appropriate depending on the nature of the product and the food allergic population (e.g., infants).
27 See “Guidance for Industry: Food Allergen Labeling Exemption Petitions and Notifications” (Ref. 16) for details regarding our recommendations for relevant clinical information to be assessed from challenge study data. The recommended clinical information includes specifying the number of individuals enrolled and challenged in each study, obtaining clinical information for each individual challenged (such as age, gender, nationality/race, skin prick test or food-specific IgE levels, history of food allergic disease (e.g., frequency and severity of prior reactions), comorbidities, and assessing information on elicited symptoms to understand potential dose-response severity.
28 The threshold ED in this case is the challenge dose interval between the highest challenge dose not to elicit an objective reaction/symptom, i.e., no observed adverse effect level (NOAEL), and the ED or LOAEL, i.e., lowest challenge dose to elicit an objective reaction (Ref. 4 and Ref. 5).
29 Obtaining reliable severity dose-response data from food challenges may be difficult because food challenges are often terminated before severe or anaphylactic responses are elicited.
30 The concentration could be obtained from the manufacturer of the food product or determined by analysis. When the concentration is known, the allergen dose exposure can be calculated by multiplying the amount of food product reported to be consumed by the concentration of allergen in that food product.
to high allergenic dose potency (when the concentration of food allergen in that small amount of food product is relatively low) or is due to a high concentration of the food allergen in that food product. In contrast, qualitative information about the amount of food product consumed (e.g., a single bite) without any quantitative information about the concentration of food allergen in that food product provides less robust information on allergenic dose potency, because it cannot distinguish between circumstances in which an IgE-mediated food allergic reaction associated with a relatively small amount of food product is due to high allergenic dose potency or is due to a high concentration of the food allergen in that food product.

Data from animal or in vitro/ex vivo models of IgE-mediated food allergy can provide information relevant to determining allergenic potency, but generally are considered supporting data that are used in combination with – not instead of – human data.

FALCPA did not discuss measures of allergenic potency, which were not generally available in 2004. See Table 5 for allergenic potency information for the already identified major food allergens based on more recent published scientific literature (Ref. 8 and Ref. 40).

<table>
<thead>
<tr>
<th>Measure of Potency</th>
<th>Milk</th>
<th>Soy</th>
<th>Peanut</th>
<th>Tree Nuts</th>
<th>Fish</th>
<th>Shellfish</th>
<th>Egg</th>
<th>Wheat</th>
<th>Sesame (effective 1/1/23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED01 (mg protein)* (Ref. 8)</td>
<td>0.3</td>
<td>0.7</td>
<td>0.7</td>
<td></td>
<td>1.3</td>
<td>30.8</td>
<td>0.2</td>
<td>1.1</td>
<td>0.2</td>
</tr>
<tr>
<td>ED50 (mg protein)* * (Ref. 40)</td>
<td>192</td>
<td>2858</td>
<td>236</td>
<td>728</td>
<td>793</td>
<td>18867</td>
<td>134</td>
<td>279</td>
<td>443</td>
</tr>
</tbody>
</table>

* ED01 represents the cumulative eliciting dose predicted to produce an IgE-mediated food allergic reaction in 1 percent of a specific allergic population.
**ED50 represents the cumulative eliciting dose predicted to produce an IgE-mediated food allergic reaction in 50 percent of a specific allergic population.

V. Identifying and Systematically Evaluating the Body of Evidence Applicable to Our Scientific Factors

In this guidance, we focus on the identification and evaluation of “historical information” – i.e., generally available information (e.g., in published scientific literature and in community reports), because in most circumstances we expect that such historical information will be the principal information that FDA staff or applicable stakeholders will consider when evaluating whether a food allergen is of public health importance. (See the definition of “historical information” in Table 1.) However, we do not intend this focus on historical information to
preclude FDA staff or applicable stakeholders from conducting new studies or otherwise obtaining information that does not satisfy the definition of “historical information.”

A. Preliminary Identification of Published Scientific Literature

FDA staff and applicable stakeholders should conduct a preliminary identification of published scientific literature applicable to our scientific factors through a systematic identification of published abstracts of available English language scientific literature. Applicable scientific literature includes published studies (such as clinical, animal, in vitro, and ex vivo studies) as well as publicly available scientific information provided by reputable national and international organizations.31

Examples of key words to use during searches are allergy, IgE and IgE-mediated, natural history, prevention, treatment/desensitization, prevalence, potency, threshold/eliciting dose, dose response, anaphylaxis, severity, cross-reactivity, adverse reactions or events, food analytical surveys, consumer studies, and quality of life.

B. Preliminary Identification of Community Reports in Surveillance Databases and Other Sources

FDA staff and applicable stakeholders should conduct a preliminary identification of community reports that are not in the published scientific literature by conducting a systematic review of:

- Publicly available surveillance databases32 (such as the CFSAN Adverse Event Reporting System (CAERS)) for:
  - Adverse event reports regarding food products that disclose the presence of the food allergen; and
  - Product complaints about food products that do not disclose the presence of the food allergen; and

- Other sources describing community reports, such as an FDA request for data and other information and information submitted to the docket established at https://www.regulations.gov for such a request.

31 An example of such an organization is the World Health Organization and International Union of Immunological Societies (WHO/IUIS) Allergen Nomenclature Sub-committee (Ref. 30).

32 FDA staff could also access information in agency databases that are not publicly available. For example, if FDA found consumer complaints in a non-public agency database, we could consider that information and, as appropriate, place redacted information into the administrative record of the rulemaking. Examples of relevant information sources are ORADDS (Office of Regulatory Affairs Reporting, Analysis, and Decision Support System) and RES (FDA Recall Enterprise System).
C. Systematic Evaluation of Published Scientific Literature and Community Reports

1. Narrowing the identified body of published scientific literature

FDA staff and applicable stakeholders should narrow the identified body of published scientific literature to those most likely to be relevant to our scientific factors before conducting a substantive review of the full text of the identified publications. One example of an approach to doing so is to systematically review and classify the scientific abstracts identified during the published scientific literature review as to their likely significance – e.g., as “critical,” “supplemental,” or “neither critical nor supplemental” as follows:

- **Examples of Scientific Abstracts that Could Be Classified as Critical**
  - Human data;
  - Exposure: oral, sublingual;
  - Study identifies and characterizes food allergenic proteins and/or food allergic individuals;
  - Original research or systematic reviews, controlled trials, experimental studies, descriptive studies (comparative, correlation, or case-controlled studies), expert committee reports, or opinions or clinical experience of respected authorities, laboratory-based studies, case reports; and
  - Study purpose relevant to incidence/prevalence/natural history; food challenge-diagnosis, threshold; treatment/management/prevention of food-induced anaphylaxis and other acute IgE-mediated food allergic reactions; analytical product surveys and/or label reviews; consumer avoidance practice surveys; quality of life

- **Examples of Scientific Abstracts that Could Be Classified as Supplemental**
  - Experimental animal data (through oral challenge route);
  - *In vitro* or *ex vivo* studies of dose response to food;
  - Non-oral route of exposure: skin, inhalation, or other non-oral route; and
  - Non IgE-mediated reactions to the food

- **Neither critical nor supplemental – articles cannot be classified as either critical or supplemental.**

Following such a classification, a more thorough review could focus on those scientific publications classified as “critical,” extend to review of scientific publications classified as “supplemental” as necessary and appropriate (e.g., if there are insufficient data and information available in scientific publications classified as “critical”), and exclude scientific publications classified as “neither critical nor supplemental.”

---

33 Non-IgE-mediated reactions to food allergens may be captured in probable food allergy rates and other community report data.
Another example of an approach to narrowing the identified body of published scientific literature to those most likely to be relevant to our scientific factors is to focus the substantive review on those scientific publications that could be scored “High” using a GRADE system (such as that shown in Table 6 in section V.C.2) if such publications applicable to our scientific factors are available.

2. Systematic evaluation of the strength of the identified evidence

FDA staff and applicable stakeholders should grade each piece of the identified body of evidence based on a strength of evidence GRADE system. See Table 6 for an example of such a GRADE system. We developed and modified the GRADE system in Table 6 from the published scientific literature (Ref. 28 and Ref. 29). We generally intend to use the GRADE system shown in Table 6 when we evaluate the strength of the identified scientific evidence.

Table 6. GRADE system for scoring the strength of the evidence applicable to each scientific factor (developed and modified from Ref. 28 and Ref. 29)

<table>
<thead>
<tr>
<th>If the factor is …</th>
<th>And the type of scientific evidence is …</th>
<th>Then the strength of the evidence is …</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence of IgE-mediated food allergy</td>
<td>Historical information of positive DBPCFC in a population of documented sensitized individuals</td>
<td>High (gold standard)</td>
</tr>
<tr>
<td>Evidence of IgE-mediated food allergy</td>
<td>Independent recognition of well-characterized proteins from the food as clinically relevant food allergens by reputable national and international organizations</td>
<td>High</td>
</tr>
<tr>
<td>Evidence of IgE-mediated food allergy</td>
<td>Historical information of typical, reproducible, and temporally-related signs or symptoms of IgE-mediated food allergic reactions in documented sensitized individuals</td>
<td>High</td>
</tr>
<tr>
<td>Evidence of IgE-mediated food allergy</td>
<td>Historical information of typical, reproducible, and temporally-related signs or symptoms of food allergic reactions in self-reported sensitized individuals</td>
<td>Medium</td>
</tr>
<tr>
<td>Evidence of IgE-mediated food allergy</td>
<td>Historical information of typical, reproducible, and temporally-related signs or symptoms of IgE-mediated food allergic reactions in individuals who are not sensitized and/or whose sensitization status is not reported</td>
<td>Low</td>
</tr>
<tr>
<td>Evidence of IgE-mediated food allergy</td>
<td>Historical information in documented or self-reported sensitized individuals who do not present typical, reproducible, and temporally-related signs or symptoms of IgE-mediated food allergic reactions</td>
<td>Low</td>
</tr>
<tr>
<td>If the factor is …</td>
<td>And the type of scientific evidence is …</td>
<td>Then the strength of the evidence is …</td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Evidence of IgE-mediated food allergy</td>
<td>Elimination diets leading to resolution of chronic signs or symptoms (e.g., eczema, gastrointestinal disturbances) in documented or self-reported sensitized individuals who do not present typical, reproducible, and temporally-related signs or symptoms of IgE-mediated food allergic reactions</td>
<td>Low</td>
</tr>
<tr>
<td>Evidence of IgE-mediated food allergy</td>
<td>Historical information regarding clinically cross-reactive food allergies to the food in individuals sensitized to other cross-reactive foods</td>
<td>Low</td>
</tr>
<tr>
<td>Prevalence</td>
<td>Epidemiological studies in U.S. general population of prevalence rate estimates in well-characterized allergic individuals</td>
<td>High</td>
</tr>
<tr>
<td>Prevalence</td>
<td>Epidemiological studies in the U.S. general population to determine probable food allergy rate in self-reported allergic individuals based on the responses to questionnaires that ask about foods that elicit an allergic reaction, signs or symptoms of the allergic reaction(s), treatment or doctor visit, diagnostic tools, and doctor diagnosis</td>
<td>High to medium</td>
</tr>
<tr>
<td>Prevalence</td>
<td>Epidemiological studies in the U.S. general population to determine probable food allergy rate in self-reported reactive individuals based on the responses to questionnaires that only ask about foods that elicit an allergic reaction (without also asking for information on signs or symptoms, treatment or doctor visit, diagnostic tools, and doctor diagnosis)</td>
<td>Medium</td>
</tr>
<tr>
<td>Prevalence</td>
<td>Epidemiological studies that look for evidence of IgE sensitization in the U.S. general population</td>
<td>Medium</td>
</tr>
<tr>
<td>Prevalence</td>
<td>Prevalence data based on sensitization rates or other clinical parameters from populations outside the United States</td>
<td>Medium to low</td>
</tr>
<tr>
<td>Prevalence</td>
<td>Prevalence data based on sensitization rates or other clinical parameters from local or regional U.S. populations (e.g., academic clinical center patient populations, individuals presenting to local or regional hospital systems)</td>
<td>Low</td>
</tr>
<tr>
<td>If the factor is …</td>
<td>And the type of scientific evidence is …</td>
<td>Then the strength of the evidence is …</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Prevalence</td>
<td>Surveys based on retrospective review of patient medical records with diagnosis codes related to food allergy</td>
<td>Low</td>
</tr>
<tr>
<td>Prevalence</td>
<td>Surveys based on review of frequency of food allergic reactions in community reports from surveillance databases</td>
<td>Low</td>
</tr>
<tr>
<td>Severity</td>
<td>Objective signs, in well-characterized allergic individuals evaluated in a clinical setting (e.g., clinic, hospital), classified according to scientifically accepted classification system, and treated</td>
<td>High</td>
</tr>
<tr>
<td>Severity</td>
<td>Documented report of fatality after exposure to a food allergen</td>
<td>High to medium</td>
</tr>
<tr>
<td>Severity</td>
<td>Objective signs, in well-characterized allergic individuals, elicited by food challenge study</td>
<td>Medium</td>
</tr>
<tr>
<td>Severity</td>
<td>Objective signs, typical of allergic reactions, reported in community reports from self-reported or well-characterized allergic individuals</td>
<td>Medium</td>
</tr>
<tr>
<td>Severity</td>
<td>Atypical and/or poorly-described objective signs reported in community reports by self-reported or well-characterized allergic individuals</td>
<td>Low</td>
</tr>
<tr>
<td>Severity</td>
<td>Subjective symptoms elicited by food challenge study in self-reported or well-characterized allergic individuals</td>
<td>Low</td>
</tr>
<tr>
<td>Potency</td>
<td>Graded food challenge studies with a wide range of doses to determine threshold EDs in adequate numbers of randomly selected well-characterized allergic individuals</td>
<td>High</td>
</tr>
<tr>
<td>Potency</td>
<td>Quantitative risk modeling of threshold EDs to food(s) from different challenge datasets to determine the distribution of EDs to food(s) in a population(s) of well-characterized allergic individuals</td>
<td>High</td>
</tr>
<tr>
<td>Potency</td>
<td>Case or community reports describing reactions to quantitatively estimated doses (amounts) of allergen in self-reported or well-characterized allergic individuals</td>
<td>Medium</td>
</tr>
<tr>
<td>Potency</td>
<td>Case or community reports describing reactions to qualitatively estimated doses (amounts) of allergen in self-reported or well-characterized allergic individuals</td>
<td>Low</td>
</tr>
</tbody>
</table>
3. Systematic evaluation of community reports

FDA staff and applicable stakeholders should group the information based on the type of community report (e.g., individual patient case study; diagnostic food allergy study; adverse event report; product complaint) before systematically evaluating the information in each community report, because the information in a community report, and the quality of such information, can vary depending on the type of community report. For example, solicited information obtained from a standardized questionnaire, information collected by objective observations, and information obtained by systematic review of reactions or reaction history by trained health care professionals are more likely to provide sufficient details to be analyzed than unsolicited information or information that is solicited without using a standardized questionnaire.

As applicable to the type of community report and the information it contains, FDA staff and applicable stakeholders should identify the following information in each report for systematic evaluation:

- Type of report (e.g., individual patient case study; diagnostic food allergy study; adverse event report; product complaint);
- Detailed information about the reporter’s food allergies (e.g., type and number of food allergies, how diagnosed and whether there is documented evidence of food-specific IgE sensitization and documented history of IgE-mediated food allergic reactions);
- Consumer demographics and other pertinent clinical history (e.g., allergic conditions, such as eczema, asthma, allergic rhinitis, chronic urticaria, drug allergy or nonallergic medical conditions and medication use); name and type of product and whether the food allergen and its food allergen source were disclosed;
- Detailed signs or symptoms (with emphasis on the severity of reaction);
- Adverse health consequences (e.g., medication use or medical visit (including hospitalization));
- Estimated amount of food product consumed;
- Estimated concentration or amount (ideally in grams of food protein) of food allergen in food product consumed;
- Photos of, or other evidence pertaining to, product labels or complaint information; and
- Other relevant information from the report narrative.

When systematically evaluating community reports classified as adverse event reports or product complaints, FDA staff and applicable stakeholders should also identify the following information:

- Number of adverse event reports and product complaints regarding a food allergen that is:
  - **Disclosure** on the label of food products; and
  - **Not disclosed** on the label of food products;
• Frequency of severe adverse reactions reported to the food allergen that is:
  o **Disclosed** on the label of food products; and
  o **Not disclosed** on the label of food products;
• The potential or suspected cause of an adverse event report or product complaint – e.g.:
  o The label is incomplete or incorrect;
  o The food allergen source of a declared ingredient is not identified;
  o A spice, flavor, or color is declared using a collective term (e.g., “spice,” “natural flavor,” “artificial flavor,” or “color”) in the ingredient list;
  o The food allergen source is a clinically cross-reactive allergen (e.g., if a consumer who is allergic to peanuts eats a product containing lupin); or
  o A food allergen appears to have been unintentionally incorporated into a food during its manufacture (e.g., because a consumer who is allergic to a particular food allergen reports a food allergic reaction to a product that does not contain that particular food allergen as an ingredient).

4. **Systematic evaluation of the severity of an IgE-mediated food allergic reaction**

FDA staff and applicable stakeholders should evaluate the severity of an IgE-mediated food allergic reaction described in the identified scientific evidence using a GRADE system. See Table 7 for an example of such a GRADE system. The GRADE system in Table 7 is adapted from the GRADE system published in Ref. 36, with some modifications to signs or symptoms that could be classified as mild, moderate, or severe based on other GRADE systems (Ref. 37) and to classify the severity of an IgE-mediated food allergic reaction based on actual adverse health consequences or interventions (e.g., medication use, hospitalization) that may be found in adverse event data or reports.

In evaluating severity of IgE-mediated food allergic reactions, FDA staff and applicable stakeholders also should consider available patient-centered information such as data from quality-of-life studies or questionnaires. Although not part of the systematic grading of severity of an IgE-mediated food allergic reaction, such information addresses other health factors or potential comorbidities associated with allergy to the food such as patients’ experiences and perspectives about IgE-mediated food allergic reactions and allergen avoidance practices that may negatively impact the quality of life and psychosocial wellbeing of these individuals and their caregivers (Ref. 2).

---

34 We generally intend to use the GRADE system shown in Table 7 when we evaluate the severity of an IgE-mediated food allergic reaction described in the identified scientific evidence.
Table 7. GRADE system for scoring severity of an IgE-mediated food allergic reaction (adapted from Ref. 36 and Ref. 37)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Objective signs or subjective symptoms within a single organ system</th>
<th>Objective signs or subjective symptoms within multiple organ systems</th>
</tr>
</thead>
</table>
| Mild  | • Skin (not generalized): eczema, erythema, flushing, pruritus, urticaria (hives), conjunctivitis, nonlaryngeal angioedema (e.g., lip swelling)  
• Gastrointestinal (GI): OAS (oral allergy syndrome), nausea alone, colic  
• Upper respiratory: rhinitis, nasal congestion, sneezing | Not applicable; when signs or symptoms appear in multiple organ systems, the signs or symptoms are considered either moderate or severe |
| Moderate | • Skin: generalized urticaria (hives), facial swelling  
• GI: abdominal pain, diarrhea, vomiting, cramps  
• Upper or mild lower respiratory: dyspnea, cough, chest or throat tightness  
• Cardiovascular/neurologic (mild): tachycardia, dizziness, near syncope, tiredness/lethargy  
• Reaction requiring emergency medical visit (no epinephrine) or loss of school/work activity | Combination of signs or symptoms in any two of the following organ systems of mild/moderate grade:  
• Skin;  
• GI;  
• Upper respiratory;  
• Mild lower respiratory; or  
• Cardiovascular/neurologic |
| Severe | • Lower respiratory: asthma, bronchoconstriction (drop in peak flow), wheezing, stridor, hoarseness, laryngeal edema (or throat closing)  
• Cardiovascular/neurologic: arrhythmia, shock, fall in blood pressure, hypotension, cyanosis  
• Anaphylaxis, collapse  
• Reaction requiring epinephrine treatment  
• Reaction requiring hospitalization  
• Death | • Any combination of severe grade signs or symptoms; or  
• Any combination of signs or symptoms in three or more organ systems of mild/moderate grade |

VI. FDA’s Evaluation of the Public Health Importance of a Non-Listed Food Allergen

In this section, we describe FDA’s evaluation of the identified body of evidence applicable to our scientific factors, FDA’s evaluation of information relevant to the labeling and production of food containing a food allergen, and how we intend to consider the total body of evidence.

**A. FDA’s Evaluation of the Identified Body of Evidence Applicable to Our Scientific Factors**

Sections VI.A.1 through VI.A.4 describe how we generally intend to weigh the evidence for each scientific factor. We generally intend this evaluation to be a case-by-case approach (Ref. 27) based on a robust identified body of evidence – i.e., an identified body of evidence that receives
a GRADE of High or Medium using the GRADE system described in Table 6. Therefore, it is unlikely that we would consider that a food or a component of food is a food allergen of public health importance if most or all of the available data and information have a GRADE of Low.

1. **Factor #1: Evidence of IgE-mediated food allergy**

As discussed in section III.A, this document addresses the food allergies that have been most studied and understood clinically – i.e., IgE-mediated food allergies. Therefore, the initial question for us to address when we evaluate the public health importance of a food or component of food as a food allergen is whether there is robust evidence that an adverse reaction to the food or component of food is IgE-mediated (Factor #1). We generally expect to GRADE data addressing this initial question as “High” or “Medium” if the data provides evidence of a two-step immune process – i.e., both sensitization and reactivity. We generally do not expect to continue to evaluate the identified body of evidence applicable to Factors #2, #3, and #4 if the identified body of evidence applicable to Factor #1 does not provide robust evidence that an adverse reaction to a food or component of food is IgE-mediated.

As discussed in section IV.A, the “gold standard” method for obtaining evidence demonstrating that an adverse reaction to a food or component of food is IgE-mediated is DBPCFC in a population of documented sensitized individuals. We recommend that any request for us to evaluate a food or component of food as a food allergen of public health importance include data from a DBPCFC in a population of documented sensitized individuals whenever possible. We generally intend to GRADE such data as “High” (see Table 6). FDA staff and applicable stakeholders should determine whether one or more proteins that are present in a food have been included in a consensus database of well-characterized allergenic proteins, such as the one maintained by the WHO/IUIS allergen nomenclature Sub-committee (Ref. 30). We generally intend to consider evidence obtained from DBPCFC in a population of documented sensitized individuals and evidence of one or more well-characterized allergenic proteins from a food, alone or in combination, as the most robust evidence supporting the initial question of whether an adverse reaction to a food or component of food is IgE-mediated.

If data from a DBPCFC in a population of documented sensitized individuals are not available, we generally intend to evaluate, on a case-by-case basis, whether other data and information that can be GRADED as “High” or “Medium,” alone or in combination, provide robust evidence that an adverse reaction to a food or component of food is IgE-mediated. For example:

- We generally intend to GRADE as “High” historical information of typical, reproducible, and temporally-related signs or symptoms of IgE-mediated food allergic reactions in documented sensitized individuals (see Table 6). Data obtained from documented sensitized individuals can reduce the potential for reported signs or symptoms of IgE-mediated food allergic reactions to be due to confounders such as an intolerance that might be associated with the food.
- We generally intend to grade as “Medium” historical information of typical, reproducible, and temporally-related signs or symptoms of IgE-mediated food allergic reactions in self-reported sensitized individuals. Because IgE sensitization to the food is self-reported but not confirmed, data obtained from self-reported sensitized
individuals can be confounded by factors such as an intolerance that might be associated with the food.

We generally intend to GRADE as “Low” historical information that fails to provide evidence of a two-step immune process – i.e., both sensitization and reactivity (see Table 6).

2. **Factor #2: Prevalence of an IgE-mediated food allergy in the U.S. population**

We recommend that any request for us to evaluate a food or component of food as a food allergen of public health importance include prevalence data with a GRADE of “High” or “Medium” as shown in Table 6. However, we recognize that there could be circumstances in which we will need to evaluate the public health importance of a food allergen with minimal prevalence information – e.g., if a food allergen that causes IgE-mediated reactions is newly introduced to the U.S. food supply and there has not been enough time to design and execute prevalence studies.

As discussed in section IV.B, prevalence rate estimations for any IgE-mediated food allergy based on DBPCFC or other robust clinical parameters are difficult to obtain at the national level, and the NASEM report (Ref. 2) did not find U.S. prevalence rate estimations for any IgE-mediated food allergy based on this type of information. Therefore, we generally expect prevalence data to be based on epidemiological studies to determine probable food allergy rates using self-reported data from questionnaires (see Table 6).

When evaluating epidemiological studies to estimate probable food allergy rates based on self-reported responses to questionnaires, the quality of evidence and information solicited, collected, and analyzed can vary widely. Thus, we generally intend to give greatest weight and GRADE (“High”) to studies using questionnaires that:

- Solicit and analyze information such as signs or symptoms, treatment or doctor visits, diagnostic tools, and doctor diagnosis in addition to self-report of food allergy;
- Are directed to a random, nationally representative population in the United States rather than to a targeted population (e.g., to persons identified by physicians as potentially allergic to a specific food allergen);
- Ask reporters about all foods that cause a food allergic reaction (rather than prompt reporters about specific foods that cause a food allergic reaction); and
- Are relatively recent (e.g., data obtained in the prior 10 years).

We generally intend to GRADE as “Medium” epidemiological studies to estimate probable food allergy rates in reactive individuals based on the responses to questionnaires that only ask about foods that elicit an allergic reaction (without also asking for any information on signs or symptoms, treatment or doctor visit, diagnostic tools, and doctor diagnosis) or the responses to questionnaires that solicit incomplete information on signs or symptoms, treatment or doctor visits, diagnostic tools, doctor diagnosis, and/or other methodologies to more effectively characterize self-reported allergic individuals.
We generally intend to GRADE as “Medium” an epidemiological study in which researchers look for evidence of IgE sensitization in blood samples collected from the general population, recognizing that this type of study could overestimate the prevalence rate of a food allergen, because some of the sensitized individuals might not be allergic individuals. See Table 6 for examples of historical information that we generally intend to GRADE as “Low.”

As shown in Table 6, we generally intend to GRADE as “Low”:

- Prevalence estimations based on sensitization rates or other clinical parameters from selected U.S. populations (e.g., clinical center patient populations, individuals presenting to local or regional hospital systems, or from other countries or geographical areas) because such data are not nationally representative of the U.S. population;
- Surveys based on retrospective review of patient medical records with diagnosis codes related to food allergy, because such diagnosis codes are not always specific for IgE-mediated food allergy; and
- Surveys based on review of frequency of IgE-mediated food allergic reactions in community reports from surveillance databases, because such reports usually do not contain sufficient information to understand the baseline frequency (or denominator) of allergy to the food in the population of reporters.

3. **Factor #3: Severity of IgE-mediated food allergic reactions**

We recommend that any request for us to evaluate a food or component of food as a food allergen of public health importance include severity data with a GRADE of “High” or “Medium” as shown in Table 6.

Any food allergen has potential to cause a wide range of clinical manifestations. These manifestations can involve a single organ system or multiple organ systems and can range from relatively mild reactions (e.g., sneezing) to severe anaphylaxis reactions that can lead to loss of consciousness, asphyxiation, or shock and can require use of epinephrine or lead to hospitalization or death. We generally intend to use the GRADE system shown in Table 7 when we evaluate:

- The actual severity of the IgE-mediated food allergic reaction; and
- The relative number and frequency of severe reactions.

To evaluate the actual severity of reported reactions to the food allergen, we generally intend to give the greatest weight to the following types of data regarding allergic signs or symptoms:

- Objective signs, in well-characterized allergic individuals, that are confirmed by a physician as IgE-mediated, classified according to scientifically accepted classification system, and treated;
Contains Nonbinding Recommendations
Draft-Not for Implementation

- Documented reports of fatality\textsuperscript{35} after exposure to the food allergen;
- Objective signs, in well-characterized allergic individuals, elicited by a food challenge study; and
- Objective signs that are typical of allergic reactions and reported in community reports from well-characterized or self-reported allergic individuals.

We generally intend to GRADE as “Low” atypical and/or poorly-described objective signs by self-reported or well-characterized allergic individuals in community reports, as well as subjective symptoms in self-reported or well-characterized allergic individuals elicited by food challenge study (see Table 6).

In evaluating the relative number and frequency of severe reactions to the food allergen, we generally intend to give the greatest weight to evidence demonstrating that:

- The food causes a high number or frequency of anaphylaxis or other severe IgE-mediated food allergic reactions per allergic individual or per population of allergic individuals;
- Reactions cause high frequency of comorbidity, including negative patient-centered impacts on quality of life; and
- Reactions cause a high number or frequency of serious public health sequelae (e.g., hospital visits), including evidence of fatality.

4. Factor #4: Allergenic potency

We recommend that any request for us to evaluate a food or component of food as a food allergen of public health importance include potency data with a GRADE of “High” or “Medium” as shown in Table 6. However, we recognize that there could be circumstances in which there will be minimal potency information – e.g., if a food allergen that causes IgE-mediated reactions has a relatively short consumption history and there has not been enough time to design and execute potency studies.\textsuperscript{36}

We generally intend to GRADE as “High” allergen potency data obtained from: (1) prospectively designed graded food challenge studies with a wide range of doses to determine threshold EDs in adequate numbers of randomly selected well-characterized allergic individuals; or (2) quantitative risk modeling studies of threshold EDs to food(s) in a population(s) of well-characterized allergic individuals (see Table 6). In evaluating such potency data, we generally intend to give the greatest weight to:

\textsuperscript{35} We generally intend to GRADE a report of a fatality after exposure to the food allergen as “High” when the reported fatality occurred in a well-characterized allergic individual and as “Medium” when there is insufficient information to confirm that the fatality occurred in a well-characterized allergic individual (see Table 6).

\textsuperscript{36} Challenge studies to evaluate the potency of a food allergen generally are conducted as part of a clinical research study, rather than as a part of the doctor diagnosis of food allergy for individual patients. Thus, potency data are generally less available than data on prevalence and severity.
• Data that provide EDs causing reactions at the mean population level (ED50) and those causing reactions in the most sensitive populations (ED1, ED5, or ED10) to allow comparisons with major food allergens; and
• Data allowing assessment of severity dose–response relationship (e.g., gradient of severity of IgE-mediated food allergic reactions) at the individual or population levels; robust evidence may include information on the relative severity of IgE-mediated food allergic reactions at different ED levels, which would enable us to identify foods with a high probability of severe reactions from low dose exposures.

We generally intend to GRADE as “Medium” allergen potency data obtained from case or community reports describing reactions to quantitatively estimated doses (amounts) of food allergen, derived from information detailing the amount of food product likely consumed during a reaction multiplied by the known or analyzed concentration (e.g., ppm) of food allergen in that food product, in self-reported or well-characterized allergic individuals (see Table 6).

We generally intend to GRADE as “Low” allergen potency data obtained from case or community reports describing reactions to qualitatively estimated doses (amounts) of allergen in self-reported or well-characterized allergic individuals (see Table 6).

In evaluating the public health importance of a food allergen based on the identified body of evidence:

• We generally intend to give the greatest weight to evidence that there is a high probability of severe reactions from low dose exposures, because the probability for adverse health consequences from inadvertently consuming these foods at relatively minor food use levels is greater.
• We also will consider the extent to which processing of the food allergen (or of food containing the food allergen) is known to impact the potency of the food allergen (e.g., if foods containing the food allergen are commonly cooked and cooking the food allergen, or food containing the food allergen, reduces the frequency dose-response or severity dose-response).

B. FDA’s Evaluation of Information Relevant to the Labeling and Production of Food Containing a Food Allergen

When we determine it to be useful to evaluate whether a food allergen is of public health importance, we may seek or request data and other information relevant to the labeling and production of food containing the food allergen, similar to the data and other information we requested for sesame. Examples of such data and other information are:

• Data and other information relevant to the prevalence in the United States of IgE-mediated food allergic reactions that could be attributed to exposure to the food allergen that is not disclosed on the label of food products;
• Prevalence and amounts of the undisclosed food allergen in foods;
• Characteristics of food products and food production practices;
C. How FDA Intends to Consider the Total Body of Evidence

We generally intend to consider whether a food allergen is of public health importance:

- Only when there is robust evidence of IgE-mediated food allergy (Factor #1);
- After considering the prevalence, severity, and potency of the food allergen (Factors #2, #3, and #4) on a case-by-case basis, because the number of permutations regarding scientific factors #2, #3, and #4 is quite large;\(^\text{37}\) and
- When applicable, after considering additional data and information regarding:
  - The prevalence in the United States of IgE-mediated food allergic reactions that could be attributed to exposure to the food allergen that is not disclosed on the label of food products;
  - Prevalence and amounts of the food allergen in foods that is not disclosed on the label of food products;
  - Characteristics of food products and food production practices;
  - Patient-centered studies or other patient-centered information; and
  - Clinically cross-reactive IgE-mediated food allergies to the food and, if relevant, whether potential cross-reactivity to the food allergen would not be well-recognized in the U.S. allergic population.

VII. Stakeholder Submission of a Citizen Petition

Any interested stakeholder may submit a citizen petition submitted in accordance with 21 CFR 10.30 asking us to evaluate the public health importance of a non-listed food allergen. In a citizen petition, applicable stakeholders should identify and evaluate the body of evidence applicable to each of the scientific factors listed in section IV of this guidance document as described in section V of this guidance. Applicable stakeholders also should provide other information, such as the information relevant to the labeling and production of food containing a food allergen as described in section VI.B of this guidance document, when such information is available and relevant to the food allergen.

\(^\text{37}\) For example, the prevalence and potency of a food allergy could be high, low, or unknown, and the severity of an IgE-mediated food allergic reaction could be mild, moderate, or severe.
VIII. References

The following references marked with an asterisk (*) are on display at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they also are available electronically at https://www.regulations.gov. References without asterisks are not on public display at https://www.regulations.gov because they have copyright restriction. Some may be available at the website address, if listed. References without asterisks are available for viewing only at the Dockets Management Staff. FDA has verified the website addresses, as of the date the notice of availability for this document publishes in the Federal Register, but websites are subject to change over time.


9. PALFORZIA. Available at https://www.fda.gov/vaccines-blood-biologics/allergenics/palforzia.*


35. GRADE. Welcome to the GRADE Working Group. Available at https://www.gradeworkinggroup.org/.


IX. Appendix A – Additional Considerations

A. “Community Reports” Regarding Food Allergens

For the purpose of this guidance, we use the term “community report” to mean a report, regarding a known or suspected food allergen in a food product, that is submitted to a surveillance database, a research query, or other request for information, or that is otherwise collected and described (e.g., as a patient case study or a diagnostic food challenge study reported in the scientific literature). A community report can be submitted or prepared by consumers (i.e., be a “self-report”), health care professionals, industry, researchers, government agencies, non-government agencies, or other stakeholders. Some community reports (such as adverse event reports and case studies) describe an allergic reaction experienced by an individual to a food product, whereas other community reports (usually called product complaints) call FDA’s attention to a potential problem or concern (such as labeling that does not disclose a food product is or contains a food allergen).

- Examples of surveillance databases are:
  - CAERS,\(^{38}\) which collects information on:
    - Adverse events regarding FDA-regulated products (such as an allergic reaction to a food product\(^{39}\)); and
    - Product complaints regarding FDA-regulated products (such as complaints about products that do not appropriately declare a major food allergen as

---

\(^{38}\) Information is submitted to CAERS through FDA’s MedWatch system (https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) or to FDA regional offices.

\(^{39}\) For example, consumers sometimes report an allergic reaction to a food product that contains an undeclared major food allergen that was not added to a food product as an ingredient, but is nonetheless present in the food product, possibly due to allergen cross-contact during production of the food product. Consumers also sometimes report an allergic reaction to a food that is or contains a food allergen that is not a major food allergen.
B. Codex Criteria for Evaluating the Public Health Importance of Food Allergens

In 1999, the World Health Organization of the United Nations convened a Food Allergens Labelling Panel to provide guidance to a Joint Expert Committee on Food Additives (JECFA), which provides scientific recommendations to the Codex Alimentarius Commission (Codex) relating to food additives and ingredients in foods. The Food Allergens Labelling Panel was asked to provide guidance on the following issues related to food allergies and intolerances:

- Identifying criteria for adding substances to the Codex list of common allergenic foods, if found to be necessary;
- Developing criteria for identifying products of foodstuffs on the Codex list for which labelling of the food source is not necessary; and
- Considering ways in which FAO and WHO could provide guidance to JECFA on a continuing basis.

In June 1999, Codex adopted a list of those foods or food products whose presence should always be declared in the list of ingredients on a food label, because of their allergenic properties (Ref. 25). This list included:

---

40 For example, some product complaints call our attention to food products that do not disclose the food allergen source of a food allergen that is not a major food allergen. Other product complaints call our attention to food products that do not disclose a food allergen that is not a major food allergen as an ingredient because our food labeling regulations allow the food allergen to be declared with a collective term such as “spice” or “flavoring.”

41 For example, the notice asked stakeholders to submit data and other information about prevalence of allergies and allergic reactions due to sesame in the United States directly to the docket established for the notice. However, our communications about the notice also directed the public to submit individual adverse event reports due to sesame to CAERS rather than to the docket established for the notice.
With respect to criteria for the addition of foodstuffs to the Codex list of common allergenic foods, the Food Allergens Labelling Panel recommended that the following criteria (the 1999 Codex criteria) be applied:

- The existence of a credible cause-and-effect relationship based upon positive double-blind, placebo-controlled food challenge or unequivocal reports of reactions with typical features of severe food allergy or intolerance reactions.
- There should be reports of severe systemic reactions following exposure to the foodstuff.
- Whereas the Food Allergens Labelling Panel recognized the ideal criterion would be prevalence data in children and adults, supported by appropriate clinical studies, i.e., a double-blind, placebo-controlled food challenge from the general population of several countries, it noted that currently such information was only available for infants, in some countries, and for some foodstuffs. Such information is rarely available for adults. As an alternative, the Food Allergens Labelling Panel agreed that the use of such available data (e.g., comparative prevalence of the specific food allergy in groups of allergy patients from several countries backed up ideally by a double-blind, placebo-controlled food challenge) would be appropriate.

In 2019, the Codex Committee on Food Labeling asked for FAO/WHO to convene an expert consultation to request from FAO/WHO scientific advice relating to the Codex list of common allergenic foods, including whether the published criteria for assessing additions and exclusions to the list is still current and appropriate and, subject to the advice from FAO/WHO on the criteria, whether there are foods and ingredients that should be added to or deleted from the list, clarification of the groupings of foods and ingredients in the list, and whether certain foods and ingredients, such as highly refined foods and ingredients, that are derived from the list of foods known to cause hypersensitivity can be exempted from mandatory declaration (Ref. 44). Starting in late November 2020, FAO/WHO held an expert consultation to address these

---

42 FALCPA directed us to conduct rulemaking to define, and permit use of, the term “gluten-free” on the labeling of foods. On August 5, 2013, FDA issued a final rule defining “gluten-free” for food labeling, which is intended to help consumers, especially those living with celiac disease, be confident that items labeled “gluten-free” meet a defined standard for gluten content (78 FR 47154). “Gluten-free” is a voluntary claim that can be used by food manufacturers on food labels if they meet all the requirements of the regulations. On August 13, 2020, FDA issued a final rule that establishes compliance requirements for the gluten-free labeling of fermented or hydrolyzed foods such as yogurt, sauerkraut, pickles, cheese, green olives, FDA-regulated beers and wines (e.g., generally those with less than 7 percent alcohol), and hydrolyzed plant proteins used to improve flavor or texture in processed foods such as soups, sauces, and seasonings (85 FR 49240).
questions. In May 2021, FAO/WHO issued a summary report, which, among other things, identified “prevalence of the immune-mediated hypersensitivity to a specific food, severity (i.e., proportion of severe objective reactions to a food/ingredient such as anaphylaxis), and the potency of food/ingredient (i.e., the amount of the food/ingredient required to cause objective signs) as the three key criteria that should be used to establish the priority allergen list” (Ref. 45).

C. Development of Other Examples of Criteria for Evaluating the Public Health Importance of Food Allergens

Scientific reviews and opinion papers from research groups or organizations have suggested revisions to the 1999 Codex criteria. For example, in 2008, the International Life Sciences Institute-Europe (ILSI-EU) recommended revising the 1999 Codex criteria (Ref. 26). The ILSI-EU revised criteria included “clinical issues (diagnosis, potency of allergen, severity of reactions), population elements (prevalence, exposure), and modulating factors (food processing).” In addition to suggesting revised criteria, ILSI-EU also provided a framework for evaluating whether a food allergen other than those included in the 1999 Codex list of common allergenic foods warranted regulation (such as labeling requirements) by weighting the available data according to quality, using a ranking derived from evidence-based medicine (Ref. 26). ILSI-EU and others subsequently evaluated the application of the revised criteria (Ref. 28 and Ref. 29). One publication concluded that the revised criteria were helpful in assessing known food allergens and excluding the food substances associated with non-IgE-mediated hypersensitivity reactions and that the framework for weighting the available data according to quality discriminated between publications that provided high, moderate, and low quality of evidence (Ref. 28). The other publication concluded that the revised criteria presented a way forward for the identification of food allergens of public health importance and for prioritization of allergen risk management and future data gathering (Ref. 29). Another publication applied a risk analysis cycle to food allergy and parameters for hazard scaling (Ref. 27).

In addition, some national regulatory/public health agencies (e.g., Health Canada (Ref. 46) and Food Standards Australia New Zealand (Ref. 47)) have developed or described criteria or types of evidence required to establish new or priority food allergens of public health importance. These criteria have largely mirrored the 1999 Codex criteria.

D. Report of the National Academies of Sciences, Engineering, and Medicine on Food Allergy

In 2016, NASEM issued a report entitled “Finding a Path to Safety in Food Allergy: Assessment of the Global Burden, Causes, Prevention, Management and Public Policy” (Ref. 2). One recommendation in the report was that “…public health authorities in individual countries decide on a periodic basis about which allergenic foods should be included in their priority lists based on scientific and clinical evidence of regional prevalence and severity of food allergies as well as allergen potency” (Ref. 2). The recommendations in the NASEM report focus on IgE-mediated food allergies, which have better defined underlying cellular mechanisms and physiological reactions.